COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS
20230346941 · 2023-11-02
Inventors
- Gordon MOODY (Gaithersburg, MD, US)
- Maria Letizia GIARDINO TORCHIA (Gaithersburg, MD, US)
- MICHAEL GLEN OVERSTREET (GAITHERSBURG, MD, US)
- Ryan GILBRETH (Gaithersburg, MD, US)
Cpc classification
A61K39/4611
HUMAN NECESSITIES
C07K14/70567
CHEMISTRY; METALLURGY
C07K14/70578
CHEMISTRY; METALLURGY
A61K39/464474
HUMAN NECESSITIES
A61P35/00
HUMAN NECESSITIES
International classification
A61K39/00
HUMAN NECESSITIES
C07K14/705
CHEMISTRY; METALLURGY
Abstract
This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.
Claims
1. An isolated nucleic acid sequence encoding a) a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen; and b) an armoring molecule, wherein the armoring molecule counters immunosuppression of a cell in a tumor microenvironment when expressed on a surface of the cell.
2. The isolated nucleic acid sequence of claim 1, wherein the antigen-binding domain comprises an antibody or antigen-binding fragment thereof.
3. The isolated nucleic acid sequence of claim 2, wherein the antigen-binding domain is a Fab or a single chain variable fragment (scFv).
4. The isolated nucleic acid sequence of claim 3, wherein the antigen-binding domain is an scFv comprising the nucleic acid sequence of SEQ ID NO: 33 or SEQ ID NO: 34.
5. The isolated nucleic acid sequence according to any of the preceding claims further encoding a transmembrane domain, a costimulatory domain, and a signal domain.
6. The isolated nucleic acid sequence of claim 5, wherein the transmembrane domain comprises a CD28 transmembrane domain.
7. The isolated nucleic acid sequence of claim 5, wherein the costimulatory domain comprises one or more of CD28, 4-1BB, CD3zeta, OX-40, ICOS, CD27, GITR, and MyD88/CD40 costimulatory domains.
8. The isolated nucleic acid sequence of claim 5, wherein the costimulatory domain comprises one or more of CD28, 4-1BB, and CD3zeta costimulatory domains.
9. The isolated nucleic acid sequence of claim 5, wherein the signal domain comprises a sequence encoding a CSFR2 signal peptide.
10. The isolated nucleic acid sequence according to any of the preceding claims a sequence encoding further comprising a hinge/spacer domain.
11. The isolated nucleic acid sequence of claim 10, wherein the hinge/spacer domain is an IgG4P hinge/spacer.
12. The isolated nucleic acid sequence of claim 1, wherein the armoring molecule is hypoxia-inducible factor 1α(HIF-1α) dominant negative (HIF 1 αDN).
13. The isolated nucleic acid sequence of claim 12, wherein HIF1αDN is encoded by the nucleic acid sequence of SEQ ID NO: 46.
14. The isolated nucleic acid of claim 1, wherein the cell surface antigen comprises one or more of CD10, CD16, CD19, CD20, CD22, CD123, CD30, CD34, CD47, CD56, CD80, CD86, CD117, CD133, CD138, CD171, CD37, CD38, CD5, CD7, CD79, 5T4, AFP, AXL, BCMA, B7H3, CDH3, CDH6, CLDN6, CLDN18, CLL-1, CMV, CS1, DLL3, DR5, FBP, GD2, GFRA1, GPA33, GPC3, IL-1-RAP, IL17RA, ITGB7, EBV, ERBB1/EGFR, ERBB2/Her-2, ERBB3, ERBB4, cMet, EGFR vIII, FAP, FOLR1, CEA, CEACAM6, EphA2, HSV-1, HSV-2, HTLV, HPV16-E6, HPV16-E7, IL13Ra2, IgK chain, LGR5, LMP1, LeY, LRP8, MG7, MR1, NRCAM, PMEL, NKG2D ligand, PRAME, PRLR, PVR, ROR1, ROR2, SSX2, STEAPI, STEAP2, TACI, TIM3, TRBC1, VEGFR-2, EPCAM1, VCAM1, VIPR2, MAGE-A1, MAGE-A3, MAGE-A4, mesothelin (MSLN), MUC1, MUC16, NY-ESO-1, WT1, PDL1, CAIX, CD70, PSMA, and PSCA.
15. A vector, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen and an armoring molecule, wherein the nucleic acid sequence comprises SEQ ID NO: 46.
16. A cell comprising the vector of claim 15 or the isolated nucleic acid of any of claims 1-14.
17. A cell, comprising: a nucleic acid sequence encoding a chimeric antigen receptor (CAR), and a HIF1αDN armoring molecule expressed on a surface of the cell.
18. The cell of claim 17, wherein the CAR comprises an antigen-binding domain, a transmembrane domain, a costimulatory domain, and a signal domain.
19. The cell of claim 18, wherein the antigen-binding domain is a Fab or a single chain variable fragment (scFv).
20. A cell, comprising: an anti-GPC3 chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the antigen binding domain comprises an antibody, Fab, or an scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 39, and wherein the VL comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 40 or SEQ ID NO: 43, a CDR2 comprising the amino acid sequence of SEQ ID NO: 41 or SEQ ID NO: 44, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 42 or SEQ ID NO: 45; and a HIF1αDN armoring molecule.
21. The cell of claim 20, wherein the VH comprises the amino acid sequence of SEQ ID NO: 27 or SEQ ID NO: 29.
22. The cell of claim 20-21, wherein the VL comprises the amino acid sequence of SEQ ID NO: 28 or SEQ ID NO: 30.
23. The cell of any of claims 20-22, wherein the HIF1αDN armoring molecule comprises the amino acid sequence of SEQ ID NO: 47.
24. The cell of any of claims 16-23, wherein the cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.
25. A method of treating cancer, comprising: administering to a subject in need thereof a cell, wherein the cell comprises a) a chimeric antigen receptor (CAR) specific for a cell surface antigen, and b) an armoring molecule, wherein the armoring molecule counters immunosuppression of the cell in a tumor microenvironment of the cancer.
26. The method of claim 25, wherein the cell surface antigen is one or more of CD10, CD16, CD19, CD20, CD22, CD123, CD30, CD34, CD47, CD56, CD80, CD86, CD117, CD133, CD138, CD171, CD37, CD38, CD5, CD7, CD79, 5T4, AFP, AXL, BCMA, B7H3, CDH3, CDH6, CLDN6, CLDN18, CLL-1, CMV, CS1, DLL3, DR5, FBP, GD2, GFRA1, GPA33, GPC3, IL-1-RAP, IL17RA, ITGB7, EBV, ERBB1/EGFR, ERBB2/Her-2, ERBB3, ERBB4, cMet, EGFRvIII, FAP, FOLR1, CEA, CEACAM6, EphA2, HSV-1, HSV-2, HTLV, HPV16-E6, HPV16-E7, IL13Ra2, IgK chain, LGR5, LMP1, LeY, LRP8, MG7, MR1, NRCAM, PMEL, NKG2D ligand, PRAME, PRLR, PVR, ROR1, ROR2, SSX2, STEAPI, STEAP2, TACI, TIM3, TRBC1, VEGFR-2, EPCAM1, VCAM1, VIPR2, MAGE-A1, MAGE-A3, MAGE-A4, mesothelin (MSLN), MUC1, MUC16, NY-ESO-1, WT1, PDL1, CAIX, CD70, PSMA, and PSCA.
27. The method of claim 26, wherein the armoring molecule a HIF1caDN armoring molecule.
28. The method of claim 27 further comprising inhibiting tumor growth, inducing tumor regression, and/or prolonging survival of the subject.
29. The method of claim 25, wherein the cell is an autologous cell.
30. The method of claim 29, wherein the autologous cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.
31. The method of any of claims 25-30, wherein the cancer is a solid tumor.
32. The method of claim 31, wherein the cancer is hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, and/or squamous cell lung carcinoma.
33. The method of claim 32, wherein the cancer is hepatocellular carcinoma.
34. The method of any of claims 26-33 further comprising administering to the subject a therapeutically effective amount of an anticancer antibody and/or a chemotherapeutic component.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The accompanying drawings are included to provide a further understanding of the methods and compositions of the disclosure. The drawings illustrate one or more embodiment(s) of the disclosure and together with the description serve to explain the principles and operation of the disclosure.
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
DETAILED DESCRIPTION
1. Definitions
[0037] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton, et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger, et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.
[0038] As used herein, the terms “comprise” and “include” and variations thereof (e.g., “comprises,” “comprising,” “includes,” and “including”) will be understood to indicate the inclusion of a stated component, feature, element, or step or group of components, features, elements or steps but not the exclusion of any other component, feature, element, or step or group of components, features, elements, or steps. Any of the terms “comprising,” “consisting essentially of,” and “consisting of” may be replaced with either of the other two terms, while retaining their ordinary meanings.
[0039] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise.
[0040] Percentages disclosed herein can vary in amount by ±10, 20, or 30% from values disclosed and remain within the scope of the contemplated disclosure.
[0041] Unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values herein that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
[0042] As used herein, ranges and amounts can be expressed as “about” a particular value or range. The term “about” also includes the exact amount. For example, “about 5%” means “about 5%” and also “.sub.5%.” The term “about” can also refer to +10% of a given value or range of values. Therefore, about 5% also means 4.5% - 5.5%, for example. Unless otherwise clear from context, all numerical values provided herein are modified by the term “about.”
[0043] As used herein, the terms “or” and “and/or” can describe multiple components in combination or exclusive of one another. For example, “x, y, and/or z” can refer to “x” alone, “y” alone, “z” alone, “x, y, and z,” “(x and y) or z,” “x or (y and z),” or “x or y or z.”
[0044] As used herein, the term “polypeptide” refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term “polypeptide” refers to any chain or chains of two or more amino acids. Thus, peptides, dipeptides, tripeptides, oligopeptides, “protein,” “amino acid chain,” or any other term used to refer to a chain or chains of two or more amino acids are included within the definition of “polypeptide,” and the term “polypeptide” can be used instead of, or interchangeably with any of these terms.
[0045] A “protein” as used herein can refer to a single polypeptide, i.e., a single amino acid chain as defined above, but can also refer to two or more polypeptides that are associated, e.g., by disulfide bonds, hydrogen bonds, or hydrophobic interactions, to produce a multimeric protein.
[0046] An “isolated” substance, e.g., isolated nucleic acid, is a substance that is not in its natural milieu, though it is not necessarily purified. For example, an isolated nucleic acid is a nucleic acid that is not produced or situated in its native or natural environment, such as a cell. An isolated substance can have been separated, fractionated, or at least partially purified by any suitable technique.
[0047] As used herein, the terms “antibody” and “antigen-binding fragment thereof” refer to at least the minimal portion of an antibody which is capable of binding to a specified antigen which the antibody targets, e.g., at least some of the complementarity determining regions (CDRs) of the variable domain of a heavy chain (VH) and the variable domain of a light chain (VL) in the context of a typical antibody produced by a B cell. Antibodies or antigen-binding fragments thereof can be or be derived from polyclonal, monoclonal, human, humanized, or chimeric antibodies, single chain antibodies, epitope-binding fragments, e.g., Fab, Fab′ and F(ab′)2, Fd, Fvs, single-chain Fvs (scFvs), single-chain antibodies, disulfide-linked Fvs (sdFvs), fragments comprising either a VL or VH domain alone or in conjunction with a portion of the opposite domain (e.g., a whole VL domain and a partial VH domain with one, two, or three CDRs), and fragments produced by a Fab expression library. ScFv molecules are known in the art and are described, e.g., in U.S. Pat. No. 5,892,019. Antibody molecules encompassed by this disclosure can be of or be derived from any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or subclass of immunoglobulin molecule.
[0048] As used herein, the term “polynucleotide” includes a singular nucleic acid as well as multiple nucleic acids, and refers to an isolated nucleic acid molecule or construct, e.g., messenger RNA (mRNA) or plasmid DNA (pDNA). The term “nucleic acid” includes any nucleic acid type, such as DNA or RNA.
[0049] As used herein, the term “vector” can refer to a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector can include nucleic acid sequences that permits it to replicate in a host cell, such as an origin of replication. A vector can also include one or more selectable marker gene and other genetic elements known in the art. Specific types of vector envisioned here can be associated with or incorporated into viruses to facilitate cell transformation.
[0050] A “transformed” cell, or a “host” cell, is a cell into which a nucleic acid molecule has been introduced by molecular biology techniques. All techniques by which a nucleic acid molecule can be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration are contemplated herein.
[0051] As used herein, the term “affinity” refers to a measure of the strength of the binding of an antigen or target (such as an epitope) to its cognate binding domain (such as a paratope). As used herein, the term “avidity” refers to the overall stability of the complex between a population of epitopes and paratopes (i.e., antigens and antigen binding domains).
[0052] As used herein, the terms “treat,” “treatment,” or “treatment of” when used in the context of treating cancer refer to reducing disease pathology, reducing or eliminating disease symptoms, promoting increased survival rates, and/or reducing discomfort. For example, treating can refer to the ability of a therapy when administered to a subject, to reduce disease symptoms, signs, or causes. Treating also refers to mitigating or decreasing at least one clinical symptom and/or inhibition or delay in the progression of the condition and/or prevention or delay of the onset of a disease or illness.
[0053] As used herein, the terms “subject,” “individual,” or “patient,” refer to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. Mammalian subjects include, for example, humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, bears, and so on.
[0054] As used herein, the term an “effective amount” or a “therapeutically effective amount” of an administered therapeutic substance, such as a CAR T cell, is an amount sufficient to carry out a specifically stated or intended purpose, such as treating or treatment of cancer. An “effective amount” can be determined empirically in a routine manner in relation to the stated purpose.
2. Overview
[0055] The present disclosure is directed to compositions and methods for treating cancer using chimeric antigen receptor (CAR) cell therapy. More particularly, the present disclosure concerns CAR cell therapies in which the transformed cells, such as T cells, express CARs that for example target Glypican-3 (GPC3). The CAR constructs transformed cells expressing the constructs, and the therapies utilizing the transformed cells disclosed herein can provide robust cancer treatments with minimized risk of cytokine release syndrome (CRS) or indiscriminate cytokine release in non-GPC3 expressing cells.
[0056] Without wishing to be bound by theory, GPC3 is believed to be a viable cancer target across multiple modalities, including bispecific T cell engagers, CAR cells, as well as monoclonal antibodies and antibody-drug conjugates (ADCs). GPC3, an onco-fetal antigen, is a GPI-linked heparin sulfate proteoglycan. GPC3 stabilizes the Wnt-Fzd interaction, stimulating Wnt signaling. GPC3 competes with Patched for Hh binding, relieving Smoothened inhibition, and inducing GPC3 degradation. Both pathways have been shown to stimulate hepatocellular carcinoma (HCC) growth. And, GPC3 expression levels have been shown to correlate with stage and grade of HCC.
[0057] Further, it is believed that GPC3 is a promising target for CAR cell therapy. Therefore, antibodies and CAR constructs derivized from these antibodies have been developed as described herein.
[0058] An additional aspect of the present disclosure includes CAR T cells, such as those targeting GPC3 and others that are armored with HIF1 aDN to protect the CAR T cells against immunosuppression associated with the hypoxic tumor microenvironment (TME), for example, of solid tumors.
3. CAR Construct Design
[0059] CAR constructs of the present disclosure can have several components, many of which can be selected based upon a desired or refined function of the resultant CAR construct. In addition to an antigen-binding domain, CAR constructs can have a spacer domain, a hinge domain, a signal peptide domain, a transmembrane domain, and one or more costimulatory domains. Selection of one component over another (i.e., selection of a specific co-stimulatory domain from one receptor versus a co-stimulatory domain from a different receptor) can influence clinical efficacy and safety profiles.
4. Antigen Binding Domain
[0060] Antigen binding domains contemplated herein can include antibodies or one or more antigen-binding fragments thereof. One contemplated CAR construct targeting GPC3 comprises a single chain variable fragment (scFv) containing light and heavy chain variable regions from one or more antibodies specific for GPC3 that are either directly linked together or linked together via a flexible linker (e.g., a repeat of GGGGS having 1, 2, 3 or more repeats).
[0061] The antigen-binding domain of a CAR as disclosed herein can vary in its binding affinity for the target protein. The relationship between binding affinity and efficacy can be more nuanced in the context of CARs as compared with antibodies, for which higher affinity is typically desirable. For example, preclinical studies on a receptor tyrosine kinase-like orphan receptor 1 (ROR1)-CAR derived from a high-affinity scFv (with a dissociation constant of 0.56 nM) resulted in an increased therapeutic index when compared with a lower-affinity variant. Conversely, other examples have been reported that engineering the scFv for lower affinity improves the discrimination among cells with varying antigen density. This could be useful for improving the therapeutic specificity for antigens differentially expressed on tumor versus normal tissues.
[0062] A variety of methods can be used to ascertain the binding affinity of the antigen-binding domain. In some embodiments, methodologies that exclude avidity effects can be used. Avidity effects involve multiple antigen-binding sites simultaneously interacting with multiple target epitopes, often in multimerized structures. Thus, avidity functionally represents the accumulated strength of multiple interactions. An example of a methodology that excludes avidity effects is any approach in which one or both of the interacting proteins is monomeric/monovalent since multiple simultaneous interactions are not possible if one or both partners contain only a single interaction site.
5. Spacer Domain
[0063] A CAR construct of the present disclosure can have a spacer domain to provide conformational freedom to facilitate binding to the target antigen on the target cell. The optimal length of a spacer domain may depend on the proximity of the binding epitope to the target cell surface. For example, proximal epitopes can require longer spacers and distal epitopes can require shorter ones. Besides promoting binding of the CAR to the target antigen, achieving an optimal distance between a CAR cell and a cancer cell may also help to occlude sterically large inhibitory molecules from the immunological synapse formed between the CAR cell and the target cancer cell. A CAR can have a long spacer, an intermediate spacer, or a shorter spacer. Long spacers can include a CH2CH3 domain (-220 amino acids) of immunoglobulin G1 (IgGI) or IgG4 (either native or with modifications common in therapeutic antibodies, such as a S228P mutation), whereas the CH3 region can be used on its own to construct an intermediate spacer (-120 amino acids). Shorter spacers can be derived from segments (<60 amino acids) of CD28, CD8a, CD3 or CD4. Short spacers can also be derived from the hinge regions of IgG molecules. These hinge regions may be derived from any IgG isotype and may or may not contain mutations common in therapeutic antibodies such as the S228P mutation mentioned above.
6. Hinge Domain
[0064] A CAR can also have a hinge domain. The flexible hinge domain is a short peptide fragment that provides conformational freedom to facilitate binding to the target antigen on the tumor cell. It may be used alone or in conjunction with a spacer sequence. The terms “hinge” and “spacer” are often used interchangeably—for example, IgG4 sequences can be considered both “hinge” and “spacer” sequences (i.e., hinge/spacer sequences).
[0065] A CAR can further include a sequence comprising a signal peptide. Signal peptides function to prompt a cell to translocate the CAR to the cellular membrane. Examples include an IgG1 heavy chain signal polypeptide, Ig kappa or lambda light chain signal peptides, granulocyte-macrophage colony stimulating factor receptor 2 (GM-CSFR2 or CSFR2) signal peptide, a CD8a signal polypeptide, or a CD33 signal peptide.
7. Transmembrane Domain
[0066] A CAR can further include a sequence comprising a transmembrane domain. The transmembrane domain can include a hydrophobic a helix that spans the cell membrane. The properties of the transmembrane domain have not been as meticulously studied as other aspects of CAR constructs, but they can potentially affect CAR expression and association with endogenous membrane proteins. Transmembrane domains can be derived, for example, from CD4, CD8α, or CD28.
8. Costimulatory Domain
[0067] A CAR can further include one or more sequences that form a co-stimulatory domain. A co-stimulatory domain is a domain capable of potentiating or modulating the response of immune effector cells. Co-stimulatory domains can include sequences, for example, from one or more of CD3zeta (or CD3z), CD28, 4-1BB, OX-40, ICOS, CD27, GITR, CD2, IL-2RP and MyD88/CD40. The choice of co-stimulatory domain influences the phenotype and metabolic signature of CAR cells. For example, CD28 co-stimulation yields a potent, yet short-lived, effector-like phenotype, with high levels of cytolytic capacity, interleukin-2 (IL-2) secretion, and glycolysis. By contrast, T cells modified with CARs bearing 4-1BB costimulatory domains tend to expand and persist longer in vivo, have increased oxidative metabolism, are less prone to exhaustion, and have an increased capacity to generate central memory T cells.
9. Cells
[0068] CAR-based cell therapies can be used with a variety of cell types, such as lymphocytes. Particular types of cells that can be used include T cells, Natural Killer (NK) cells, Natural Killer T (NKT) cells, Invariant Natural Killer T (iNKT) cells, alpha beta T cells, gamma delta T cells, viral-specific T (VST) cells, cytotoxic T lymphocytes (CTLs), and regulatory T cells (Tregs). In one embodiment, CAR cells for treating a subject are autologous. In other embodiments, the CAR cells may be from a genetically similar, but non-identical donor (allogeneic).
10. CAR Cell Production
[0069] CAR constructs of the present disclosure can include some combination of the modular components described herein. For example, in some embodiments of the present disclosure, a CAR construct comprises a GPC3 scFv antigen-binding domain. In some embodiments, a CAR comprises a GPC3-2 scFv antigen-binding domain. In some embodiments of the present disclosure, a CAR construct comprises a CSFR2 signal peptide. In some embodiments, a CAR construct comprises an IgG4P hinge/spacer domain carrying an S228P mutation. In some embodiments, a CAR construct comprises a CD28 transmembrane.
[0070] Different co-stimulatory domains can be utilized is the CAR constructs of the present disclosure. In some embodiments, a CAR construct comprises a co-stimulatory domain from the intracellular domain of CD3z. In some embodiments, a CAR construct comprises a CD28 co-stimulatory domain. In some embodiments, a CAR construct comprises a 4-1BB co-stimulatory domain. In some embodiments, a CAR construct comprises co-stimulatory domains from CD3z and CD28. In some embodiments, a CAR construct comprises co-stimulatory domains from CD3z and 4-1BB. In some embodiments, a CAR construct comprises co-stimulatory domains from all of CD3z, CD28, and 4-1BB. In some embodiments, a CAR construct comprises co-stimulatory domains from ICOS, OX-40, and/or GITR.
11. CAR Construct Assessment
[0071] Constructs of the present disclosure were compared and assessed based on safety as well as persistence and establishment of central memory. The lower affinity (high off-rate) scFv, GPC3, was assessed favorably on account of its improved safety. The 4-1BB and CD3z co-stimulatory domains (both in the same construct) were assessed favorably based on their contribution to improved persistence and favorable in vivo phenotype (more central memory).
12. CAR Embodiments
[0072] In some embodiments, the present disclosure provides an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) that comprises an antigen-binding domain specific for a surface antigen on a tumor cell. In some embodiments, the cell surface antigen is a protein, a phosphorylated protein, a peptide-MHC, a carbohydrate, or a glycolipid molecule.
[0073] Examples of contemplated cell surface antigens include CD10, CD16, CD19, CD20, CD22, CD123, CD30, CD34, CD47, CD56, CD80, CD86, CD117, CD133, CD138, CD171, CD37, CD38, CD5, CD7, CD79, 5T4, AFP, AXL, BCMA, B7H3, CDH3, CDH6, CLDN6, CLDN18, CLL-1, CMV, CS1, DLL3, DR5, FBP, GD2, GFRA1, GPA33, GPC3, IL-1-RAP, IL17RA, ITGB7, EBV, ERBB1/EGFR, ERBB2/Her-2, ERBB3, ERBB4, cMet, EGFR vIII, FAP, FOLR1, CEA, CEACAM6, EphA2, HSV-1, HSV-2, HTLV, HPV16-E6, HPV16-E7, IL13Ra2, IgK chain, LGR5, LMP1, LeY, LRP8, MG7, MR1, NRCAM, PMEL, NKG2D ligand, PRAME, PRLR, PVR, ROR1, ROR2, SSX2, STEAPI, STEAP2, TACI, TIM3, TRBC1, VEGFR-2, EPCAM1, VCAM1, VIPR2, MAGE-A1, MAGE-A3, MAGE-A4, mesothelin (MSLN), MUC1, MUC16, NY-ESO-1, WT1, PDL1, CAIX, CD70, PSMA, and PSCA. Other cell surface antigens are also contemplated herein.
[0074] In some embodiments, the present disclosure provides an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) that comprises an antigen binding domain specific for glypican 3 (GPC3). The antigen binding domain has an equilibrium dissociation constant (K.sub.D) of about 100 nanomolar (nM) or less, and the CAR construct does not induce cytokine production in GPC3- cells. In some embodiments, the antigen-binding domain includes an antibody or antigen-binding fragment thereof. The antigen-binding domain can be a Fab or a single chain variable fragment (scFv). In some embodiments, the antigen-binding domain is an scFv comprising the nucleic acid sequence of SEQ ID NO: 33 or SEQ ID NO: 34.
[0075] In some embodiments, the CAR further includes a transmembrane domain, a costimulatory domain, and a signal domain. The transmembrane domain can be a CD28 transmembrane domain. The costimulatory domain can be one or more of CD3zeta (or CD3z), CD28, 4-1BB, OX-40, ICOS, CD27, GITR, CD2, IL-2RP and MyD88/CD40costimulatory domains. In one specific embodiment, the costimulatory domain is one or more of CD28, 4-1BB, and CD3zeta costimulatory domains. The signal domain can be a sequence encoding a CSFR2 signal peptide.
[0076] In some embodiments, the isolated nucleic acid sequence can include a hinge/spacer domain. The hinge/spacer domain can be an IgG4P hinge/spacer.
[0077] In some specific embodiments, an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) can have the sequence of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, or SEQ ID NO: 26.
[0078] In other embodiments, the present disclosure provides an anti-GPC3 chimeric antigen receptor (CAR) including an antigen-binding domain. The antigen-binding domain can be an antibody, Fab, or scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL). In some embodiments, the VH can have a CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, the VL can have a CDR1 comprising the amino acid sequence of SEQ ID NO: 40 or SEQ ID NO: 43, a CDR2 comprising the amino acid sequence of SEQ ID NO: 41 or SEQ ID NO: 44, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 42 or SEQ ID NO: 45.
[0079] In some embodiments, the VH can be the amino acid sequence of SEQ ID NO: 27 or SEQ ID NO: 29, and the VL can be the amino acid sequence of SEQ ID NO: 28 or SEQ ID NO: 30. In some embodiments, the CAR further can have a transmembrane domain, a costimulatory domain, and a signal domain.
[0080] In some specific embodiments, the anti-GPC3 CAR can have the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 25.
[0081] In other embodiments, the present disclosure provides a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR). The nucleic acid sequence can be SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 26, SEQ ID NO: 33, or SEQ ID NO: 34.
[0082] In other embodiments, the present disclosure provides a cell comprising a vector having a nucleic acid sequence of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 26, SEQ ID NO: 33, or SEQ ID NO: 34.
[0083] In other embodiments, the present disclosure provides a cell having a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain specific for glypican 3 (GPC3), wherein the antigen binding domain has an equilibrium dissociation constant (K.sub.D) of about 100 nanomolar (nM) or less, and wherein the CAR construct does not induce cytokine production in GPC3- cells. For example, the nucleic acid sequence can be SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 26, SEQ ID NO: 33, or SEQ ID NO: 34.
[0084] In other embodiments, the present disclosure provides a cell expressing an anti-GPC3 chimeric antigen receptor (CAR) on an extracellular surface thereof. The CAR can have an antigen-binding domain that can be an antibody, a Fab, or an scFv each having a heavy chain variable region (VH) and a light chain variable region (VL). The VH can include a CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 39. The VL can include a CDR1 comprising the amino acid sequence of SEQ ID NO: 40 or SEQ ID NO: 43, a CDR2 comprising the amino acid sequence of SEQ ID NO: 41 or SEQ ID NO: 44, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 42 or SEQ ID NO: 45.
[0085] In some embodiments, the VH can have the amino acid sequence of SEQ ID NO: 27 or SEQ ID NO: 29. In some embodiments, the VL can have the amino acid sequence of SEQ ID NO: 28 or SEQ ID NO: 30. The CAR can further include a transmembrane domain, a costimulatory domain, and a signal domain. The cell express a CAR having an amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 25.
[0086] In some embodiments, the present disclosure provides a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and/or a regulatory T cell that express a CAR on an extracellular surface thereof, and the CAR can have an amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 25. Such cells can exhibit an anti-tumor immunity upon contacting a tumor cell expressing GPC3.
13. Treatment of Cancers with CARs
[0087] In some embodiments, the present disclosure provides CAR cells for treatment of cancer. The compositions (e.g., antibodies, CAR constructs, and CAR cells) and methods of their use described herein are especially useful for inhibiting neoplastic cell growth or spread. In some aspects, they are particularly useful for inhibiting neoplastic cell growth in which GPC3 plays a role.
[0088] Neoplasms treatable by the compositions of the disclosure include solid tumors, for example, those of the liver, lung, or ovary. However, the cancers listed herein are not intended to be limiting. For example, types of cancer that are contemplated for treatment herein include, for example, NSCLC, advanced solid malignancies, biliary tract neoplasms, bladder cancer, colorectal cancer, diffuse large b-cell lymphoma, esophageal neoplasms, esophageal squamous cell carcinoma, extensive stage small cell lung cancer, gastric adenocarcinoma, gastric cancer, gastroesophageal junction cancer, head and neck cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, lung cancer, melanoma, mesothelioma, metastatic clear cell renal carcinoma, metastatic melanoma, metastatic non-cutaneous melanoma, multiple myeloma, nasopharyngeal neoplasms, non-Hodgkin lymphoma, ovarian cancer, fallopian tube cancer, peritoneal neoplasms, pleural mesothelioma, prostatic neoplasms, recurrent or metastatic PD-L1 positive or negative SCCHN, recurrent squamous cell lung cancer, renal cell cancer, renal cell carcinoma, SCCHN, hypo pharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, small cell lung cancer, squamous cell carcinoma of the head and neck, squamous cell lung carcinoma, TNBC, transitional cell carcinoma, unresectable or metastatic melanoma, urothelial cancer, and urothelial carcinoma.
[0089] In one embodiment, cancers contemplated for treatment here include any that express GPC3 on the cell surfaces of the cancer cells. In one specific example, cancers contemplated for treatment herein include hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, and squamous cell lung carcinoma.
14. Armoring
[0090] In some embodiments, the present disclosure provides “armored” cells, such as CAR T cells that have one or more genetic modifications that enhance or optimize cell function by protecting the cell against an environmental insult, such as an immunosuppressive cytokine or an immunosuppressive TME. Genetic modifications include, but are not limited to, enhanced secretion of cytokines, expression of ligands that interact with immune cells such as T cell, macrophages, and regulatory T cells, or an alteration of functional characteristics. One of skill in the art will understand that armoring a cell, such as a T cell, can provide many additional benefits not described herein that allow for T cell survival in the immunosuppressive TME.
[0091] In some embodiments, a cell can include a chimeric antigen receptor (CAR) comprising a tumor specific antigen binding domain, wherein the antigen binding domain comprises an antibody, Fab, or an scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL); and a hypoxia-inducible factor 1α(HIF-1α) dominant negative (HIF 1aDN) armoring molecule.
[0092] In some embodiments, an armored cell can include a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain specific for glypican 3 (GPC3), wherein the antigen binding domain has an equilibrium dissociation constant (K.sub.D) of about 100 nanomolar (nM) or less, wherein the CAR construct does not induce cytokine production in GPC3- cells, and wherein the cell expresses a HIF1αDN armor molecule.
[0093] In some embodiments, an armored cell can include an anti-GPC3 chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the antigen binding domain comprises an antibody, Fab, or an scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 39, and wherein the VL comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 40 or SEQ ID NO: 43, a CDR2 comprising the amino acid sequence of SEQ ID NO: 41 or SEQ ID NO: 44, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 42 or SEQ ID NO: 45; a HIF1αDN armoring molecule.
15. Methods of Treatment
[0094] CAR-modified cells of the present invention, such as CAR T cells, may be administered alone or as a pharmaceutical composition with a diluent and/or other components associated with cytokines or cell populations. Briefly, pharmaceutical compositions of the invention can include, for example, CAR T cells as described herein, with one or more pharmaceutically or physiologically acceptable carrier, diluent, or excipient. Such compositions can comprise buffers such as neutral buffered saline, buffered saline, and the like; sulfates; carbohydrates such as glucose, mannose, sucrose, or dextrans, mannitol; proteins, polypeptides, or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The pharmaceutical compositions of the invention may be adapted to the treatment (or prophylaxis).
[0095] The CAR-modified cells can also be administered in conjunction with one or more additional therapies. In one embodiment, the additional therapies can include anti-cytokine antibodies. For example, one or more anti-TNFa antibodies can be used to attenuate toxicity and promote anti-tumor activity at higher CAR T doses, which can be associated with CRS-like symptoms and weight loss.
[0096] The number of CAR cells administered per dose, the number of doses, and frequency of dosing will depend on various parameters such as the patient's age, weight, clinical assessment, tumor type, tumor burden, and/or other factors, including the judgment of the attending physician. Any acceptable route of administration is contemplated, such as, without limitation, administration intravenous (e.g., intravenous infusion), parenteral, or subcutaneous routes of administration.
[0097] In a particular embodiment, a treatment regimen contemplated can include one or more biological components, such as a CAR T cell and an anticancer antibody and/or a chemotherapeutic component. For example, it is contemplated that a treatment regimen can additionally include an immune checkpoint inhibitor (ICI), such as those that target the PD-1/PD-L1 axis (PDX) and other immune-oncology (IO) treatments, such as immune system agonists.
[0098] Contemplated antibodies include an anti-PD-L1 antibody such as durvalumab (MEDI4736), avelumab, atezolizumab, KN035, an anti-PD-1 antibody such as nivolumab, pembrolizumab, REGN2810, SHR1210, IBI308, PDR001, Anti-PD-1, BGB-A317, BCD-100, and JS001, and an anti-CTLA4 antibody, such as tremelimumab or ipilimumab. Additional antibodies are also contemplated herein. Any therapeutically effective antibody subparts are also contemplated herein.
[0099] Information regarding durvalumab (or fragments thereof) for use in the methods provided herein can be found in U.S. Pat. Nos. 8,779,108; 9,493,565; and 10,400,039 the disclosures of which are incorporated herein by reference in their entirety. In a specific aspect, durvalumab or an antigen-binding fragment thereof for use in the methods provided herein comprises the variable heavy chain and variable light chain CDR sequences of the 2.14H90PT antibody as disclosed in the aforementioned U.S. patents.
[0100] Information regarding tremelimumab (or antigen-binding fragments thereof) for use in the methods provided herein can be found in U.S. Pat. No. 6,682,736 (in which tremelimumab is referred to as 11.2.1), the disclosure of which is incorporated herein by reference in its entirety.
[0101] Additional therapeutics (chemotherapies or biologics) contemplated herein include without limitation cisplatin/gemcitabine or methotrexate, vinblastine, ADRIAMYCIN™ (doxorubicin), cisplatin (MVAC), carboplatin-based regimen, or single-agent taxane or gemcitabine, temozolomide, or dacarbazine, vinflunine, docetaxel, paclitaxel, nab-paclitaxel, Vemurafenib, Erlotinib, Afatinib, Cetuximab, Bevacizumab, Erlotinib, Gefitinib, and/or Pemetrexed. Further examples include drugs targeting DNA damage repair systems, such as poly (ADP-ribose) polymerase 1 (PARP1) inhibitors and therapeutics inhibiting WEEl protein kinase activity, ATR protein kinase activity, ATM protein kinase activity, Aurora B protein kinase activity, and DNA-PK activity.
[0102] Any therapeutic compositions or methods contemplated herein can be combined with one or more of any of the other therapeutic compositions and methods provided herein.
[0103] In some embodiments, the present disclosure provides a method of treating cancer including administering to a subject in need thereof an effective amount of a cell comprising an anti-GPC3 chimeric antigen receptor (CAR) comprising an antigen-binding domain and an armoring molecule that counters immunosuppression of the cell in a tumor microenvironment when expressed on a surface of the cell. In another aspect, the discolure describes antigen-binding domain can be an antibody, Fab, or scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL). The VH can include a CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 39. The VL can include a CDR1 comprising the amino acid sequence of SEQ ID NO: 40 or SEQ ID NO: 43, a CDR2 comprising the amino acid sequence of SEQ ID NO: 41 or SEQ ID NO: 44, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 42 or SEQ ID NO: 45. In some embodiments, the method further inhibits tumor growth, induces tumor regression, and/or prolongs survival of the subject.
[0104] In some embodiments, the armoring molecule is HIF1αDN.
[0105] In some embodiments, the cell is an autologous cell. For example, the autologous cell can be selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.
[0106] In some embodiments, the cancer treated by the method is a solid tumor. For example, the cancer can be hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, and/or squamous cell lung carcinoma. In a specific embodiment, the cancer is hepatocellular carcinoma.
[0107] It is to be understood that the particular aspects of the specification are described herein are not limited to specific embodiments presented, and can vary. It also will be understood that the terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting. Moreover, particular embodiments disclosed herein can be combined with other embodiments disclosed herein, as would be recognized by a skilled person, without limitation.
Examples
[0108] The Examples that follow are illustrative of specific embodiments of the disclosure, and various uses thereof. They are set forth for explanatory purposes only and should not be construed as limiting the scope of the disclosure in any way. A description of terms is provided in Table 1.
TABLE-US-00001 TABLE 1 Description of terms Term Description GPC3-1 Anti-GPC3 scFv (lower affinity) GPC3-2 Anti-GPC3 scFv (higher affinity) GPC3-4 Prior art anti-GPC3 scFv GPC3-3 Prior art anti-GPC3 scFv BZ Intracellular domain of CAR with two co-stimulatory domains of 4-1BB and CD3zeta TZ Intracellular domain of CAR with a truncated CD3zeta signaling domain (acting as a signaling incompetent control) 28Z Intracellular domain of CAR with two co-stimulatory domains of CD28 and CD3zeta 28BZ Intracellular domain of CAR with three co-stimulatory domains of CD28, 4-1BB, and CD3zeta HIF1αDN Dominant-negative HIF-1α molecule GPC3-1 BZ CAR with GPC3 scFv, CSFR2 signal peptide, IgG4P hinge region, and both 4-1BB and CD3z co-stimulatory domains GPC3-2 BZ CAR with GPC3-2 scFv, CSFR2 signal peptide, IgG4P hinge region, and both 4-1BB and CD3z co-stimulatory domains aCART-H CAR T cell with GPC3 scFv, CSFR2 signal peptide, IgG4P hinge region, and both 4-1BB and CD3z co-stimulatory domains and armored with HIF1αDN CSFR2 Signal peptide used in all CAR constructs IgG4P Hinge sequence used in all CAR constructs Hep3B Hepatocellular carcinoma model HUH7 Resistant hepatocellular carcinoma (HCC) model
Example 1: Armoring of GPC3 CAR T Cells with HIFlcaDN Produces Less Differentiated Cells
Summary
[0109] In the present example, armoring of GPC3 BZ CAR T cells with a dominant negative HIF-1α(HIF1αDN) molecule was examined as a potential way to protect CAR T cells against hypoxia-associated immunosuppression to improve CAR T effector function and tumor control. Methods
[0110]
[0111]
[0112]
[0113]
[0114]
Results
[0115] Expression of the dominant-negative HIFla was confirmed by Real-Time PCR, while expression of endogenous HIFla was investigated by western blot. Dominant negative HIFIla was overexpressed compared to the endogenous HIFla. Moreover, expression of the DN did not alter the hypoxia-induced stabilization of the endogenous HIF 1a detected by western blot (
[0116] T cell fitness and persistence in the tumor microenvironment is related to their differentiation status (Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017). Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. CellMetab, 26(1), 94-109.). To investigate the effect of HIF1αDN expression on T cell differentiation, we analyzed the frequency of CD62L.sup.lowCD45RO.sup.hiT effector memory cells in GPC3-1 or GPC3-1 HIF1αDN CAR-T after 6 days of normoxic (20% O.sub.2) or hypoxic (1% O.sub.2) expansion. GPC3-1 HIF1αDN maintained a less differentiated phenotype as judged by the decreased frequency of T.sub.EM in both hypoxic and normoxic consitions compared to unarmored CAR-T (see
[0117] HIF1α is not only a master regulator of the hypoxic response, but also a key intermediate of T cell activation in normoxia and it is associated to the regulation of multiple signaling and metabolic pathways. To have a comprehensive view of the genetic changes induced by expression of HIF1αDN, we performed nanostring analysis on purified GPC3-1 or GPC3-1 HIF1αDN CAR-T expanded under normoxic (20% O.sub.2) conditions. HIF1αDN CAR T cells have increased expression of genes associated with stemness and decreased expression of effector function-associated genes compared to unarmored CAR T cells. Therefore, this result confirms that expression of HIF1αDN is associated to a less activated and differentiated phenotype (see
[0118] Resting T cells utilize an energy efficient oxidative metabolism but switch to a highly glycolytic metabolism when stimulated to growth or after pathogen encounter (Michalek, R. D., & Rathmell, J. C. (2010). The metabolic life and times of a T-cell. Immunol Rev, 236, 190-202.). To investigate the effect of HIF1αDN expression on the metabolic status of CAR-T cells, we evaluated glycolysis by analyzing the extracellular acidification rate (ECAR) and mitochondrial oxidative phosphorylation on the basis of the oxygen consumption rate (OCR), through real-time and live cell analysis (Seahorse XF) in basal conditions and after antigen exposure. In basal conditions, HIF1αDN CAR T cells exhibited a lower OCR and greater ECAR, indicating that they were more glycolitic. In contrast, upon antigen exposure, HIF1αDN gained 60% of OCR compared to only 20% of the unarmored. Conversly, the ECAR gain post-activation for the unarmored was 340% while only 100% for the armored CAR-T. Therefore expression of HIF1αDN rewire cell metabolism and endows CAR-T with the ability to respond to increased energy demand under stress (See
Conclusion
[0119] The characteristics of the T cells that are used to mount an anti-cancer immune response are a critical factor in determining clinical outcome. In particular, treatment of cancer using T cells with characteristics of heightened cellular longevity is associated with improved anti-tumor response (Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017). Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. CellMetab, 26(1), 94-109). Hypoxia and the HIF signaling pathway impact on imune cell fate and function, including the upregulation of glycolytic gene expression. As a result, hypoxia drives cells toward a more differentiated status that is associated to short persistence in the tumor and poor outcome. (Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017). Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. CellMetab, 26(1), 94-109.; Krzywinska, E., & Stockmann, C. (2018). Hypoxia, Metabolism and Immune Cell Function. Biomedicines, 6(2)). Our data demonstrate that CAR-T expressing HIF 1aDN maintain a naive and less activated phenotype compared to unarmored CAR T cells as shown by analysis of surface markers, gene expression, and mitochondrial function. These observations indicate that HIF1 aDN CAR T cells are well adapted to withstand immunosuppressive effects associated with the harsh hypoxic TME of solid tumors.
Example 2 Functional Responses of HIF1αDN CAR T cells Upon Target Exposure Summary
[0120] In the present example, degranulation, cytotoxicity, effector cytokine production, in vitro killing, and proliferative responses were determined in HIFl aDN CAR T cells in association with exposure to target antigen GPC3.
Methods
[0121]
[0122]
[0123]
[0124]
[0125]
[0126]
[0127]
[0128]
[0129]
[0130]
[0131] HIF1αDN CAR T have a less differentiated and activated phenotype, therefore we wanted to test if they were able to mount an effective antigen-specific immune response. GPC3-1 CAR-T cells expanded in normoxia degranulated shortly after exposure to GPC3+ Hep3B, and the extent of degranulation was slightly decreased if cells were expanded under hypoxic conditions. HIF1αDN CAR T cells expanded under normoxic conditions were able to degranulate similarly to unarmored CAR-T; however, there was no reduction of degranulation if expanded under hypoxic conditions. Degranulation was antigen-specific as shown by absence of CD107 .sup.+ cells after incubation with SNU-182. This result shown that HIF1αDN CAR T can effectively and specifically degranulate in response to antigen encounter even if expanded in hypoxia (see
[0132] Cytokine secretion is a hallmark of T cell activation; therefore, we wanted to investigate the impact of HIF1αDN expression on antigen-dependent effector cytokine production. HIF1αDN CAR T cells produce less IFNγ and IL-2, but similar amounts of TNF-α upon exposure to GPC3 as unarmored CAR T cells under normoxic and hypoxic conditions. These data demonstrate that even if HIF1 aDN CAR T have a less differentiated phenotype they can secrete substantial amount of effector cytokines in an antigen-dependent way. See
[0133] T cells that produce multiple cytokines, so-called “polyfunctional” T cells, provide a more effective immune response than do cells that produce only a single cytokine. The frequency of unarmored and armored CD4 and CD8 T cells producing the three major effector cytokines IFN-γ/IL-2.sup.+/TNFa.sup.+ upon antigen stimulation was similar between unarmored and armored when cells were exposed to the antigen in normoxic consitions. Stimulation in hypoxia profoundly decreased the frequency of unarmored polyfunctional T cells. In contrast, the frequency of polyfunctional HIF1αDN CAR-T was only slightly affected by hypoxia (See
[0134] Killing of target cells is the most important feature of CAR-T cells; therefore, we analyzed the ability of GPC3 HIF1αDN CAR T to kill target cells expressing various levels of GPC3. Expression of HIF1αDN is associated with a less differentiated phenotype; therefore, we hypothesized that HIF1αDN would persist longer than their unarmored counterparts but would also kill target cells more slowly. Unexpectedly, HIF1αDN CAR T cells under either normoxic or hypoxic conditions killed Hep3B cells faster than unarmored CAR T cells. Hep3B target cells showed a distinct and pronounced pre-apoptotic appearance after only 3 hours upon exposure to HIF1αDN CAR T (See
[0135] HIFl a is stabilized in T cells upon antigen recognition and it is an important mediator of T cell activation, therefore we asked if the expression of the DN resulted in altered T cell proliferation. CFSE labeled UT, GPC3, and GPC3 HIF1αDN CAR T cells were left unstimulated or co-cultured with Hep3B or HUH7. CFSE is progressively diluted within daughter cells following each cell division, dilution being proportional to the extent of proliferation. Flow cytometric analysis after 3 days showed that HIF1 aDN CAR T cells proliferated similarly to unmodified CAR T cells in response to target cells expressing high and low GPC3. Expression of HIF1 aDN reverts non-specific proliferation of unmodified CAR T cells in the absence of antigen, in line with its less differentiated phenotype. This result shows that blocking the HIF 1 a pathway with ectopic expression of a dominant negative molecule does not impair antigen-induced CAR-T cell proliferation (see
Conclusion
[0136] HIF1αDN CAR T cells were able to to kill GPC3.sup.+cancer cells while maintaining a less active and more naive phenotype. Moreover, expression of HIF1αDN partially protected CAR-T cells from hypoxia-induced loss of polyfunctionality. Surprisingly, HIF1αDN CAR T cells demonstrated an enhanced ability to kill certain target cells compared to unarmored CAR T cells in vitro under both normoxic and hypoxic conditions. These surprising results indicate that armoring CAR T cells with HIF1αDN may provide improved cytolytic efficacy to CAR T cells in a way unrelated to providing resistance to hypoxia.
EXAMPLE 3: expression of HIF1αDN improved CAR-T In vivo Efficacy Summary
[0137] In the present example, the effectiveness of HIF1αDN armored CAR-T cells against GPC3.sup.+tumor cells was determined in vivo in two different xenograft model.
Methods
[0138] The hepatocellular carcinoma Huh7 was used to test the in vivo effectiveness of HIF1αDN armored CAR-T cells in reducing tumor volume. Tumor cells were implanted in the flank of NSG mice (10 mice/group). When tumors reached an average volume of 150 mm.sup.3, mice were dosed with 7 ×10.sup.6 of the indicated CAR-T or 7 million of untransduced T cells and tumors measured bi-weekly (see
[0139] The hepatocellular carcinoma Hep3B was used to test the in vivo effectiveness of HIF1αDN armored CAR-T cells in reducing tumor volume. Tumor cells were implanted in the flank of NSG mice (10 mice/group). When tumors reached an average volume of 150 mm.sup.3, mice were dosed with 7×10.sup.6 of the indicated CAR-T or 7 million of untransduced T cells and tumors measured bi-weekly (see
[0140] Ex vivo analysis was performed on Huh7 tumor bearing mice dosed with 7×10.sup.6CAR-T. Four days after infusion tumors were collected from 5 mice per group. The number of CD45+cells was calculated by flow cytometry using AccuCheck Counting Beads. (See
[0141] Mice bearing Hep3B tumors were dosed with 7×10.sup.6CAR-T cells. For IFNγ analysis, blood was harvested in small volumes seven days after CAR-T infusion and serum separated using BD Microtainer Serum Separator Tubes. IFNγ levels were determined using MSD assays (See
[0142] Mice bearing Hep3B tumors were dosed with 7×10.sup.6CAR-T cells. Four days after infusion, spleen and tumors were collected and the expression of CD27 and CD70 was evaluated by flow cytometry staining. (See
Results
[0143] GPC3 HIF1αDN CAR-T cells were able to control more effectively HUH7 and induced Hep3B tumor regression faster than their unarmoured counterparts (see
[0144] Conclusion GPC3 CAR-T expressing HIF1αDN induced faster tumor regression than unarmoured GPC3 CAR-T. Tumor regression was associated to a significant increase in the ability of the cells to infiltrate and proliferate in the tumor. Moreover, although armored cells were fully activated in the tumor, they expressed less CD70 than unarmored CAR-T in the spleen, suggesting that they can maintain a less activated status even in vivo. Overall, these observation indicate that blocking the HIF1αpathway by expression of a dominant negative HIFla improve CAR-T cells in vivo efficacy while preserving a less activated and differentiated phenotype.
[0145] The embodiments described herein can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the embodiments claimed. Thus, it should be understood that although the present description has been specifically disclosed by embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of these embodiments as defined by the description and the appended claims. Although some aspects of the present disclosure can be identified herein as particularly advantageous, it is contemplated that the present disclosure is not limited to these particular aspects of the disclosure.
[0146] Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
[0147] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group.
[0148] It should it be understood that, in general, where the disclosure, or aspects of the disclosure, is/are referred to as comprising particular elements and/or features, certain embodiments of the disclosure or aspects of the disclosure consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein.
[0149] All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as ifeach independent patent and publication was specifically and individually indicated to be incorporated by reference. Citation or identification of any reference in any section of this application shall not be construed as an admission that such reference is available as prior art to the present invention.
TABLE-US-00002 TABLE 5 Sequences used in the Examples. SEQ ID NO: 1 GPC3 scFv amino acid sequence SEQ ID NO: 2 GPC3-2 scFv amino acid sequence SEQ ID NO: 3 GPC3 BZ CAR amino acid sequence SEQ ID NO: 4 GPC3 TZ CAR amino acid sequence SEQ ID NO: 5 GPC3 28Z CAR amino acid sequence SEQ ID NO: 6 GPC3 28 BZ CAR amino acid sequence SEQ ID NO: 7 GPC3-2 BZ CAR amino acid sequence SEQ ID NO: 8 GPC3-2 TZ CAR amino acid sequence SEQ ID NO: 9 GPC3-2 28Z CAR amino acid sequence SEQ ID NO: 10 GPC3-2 28BZ CAR amino acid sequence SEQ ID NO: 11 GPC3 BZ CAR nucleic acid sequence SEQ ID NO: 12 GPC3 TZ CAR nucleic acid sequence SEQ ID NO: 13 GPC3 28Z CAR nucleic acid sequence SEQ ID NO: 14 GPC3 28BZ CAR nucleic acid sequence SEQ ID NO: 15 GPC3-2 BZ CAR nucleic acid sequence SEQ ID NO: 16 GPC3-2 TZ CAR nucleic acid sequence SEQ ID NO: 17 GPC3-2 28Z CAR nucleic acid sequence SEQ ID NO: 18 GPC3-2 28BZ CAR nucleic acid sequence SEQ ID NO: 19 GPC3-3 BZ CAR amino acid sequence SEQ ID NO: 20 GPC3-3 28BZ CAR amino acid sequence SEQ ID NO: 21 GPC3-4 BZ CAR amino acid sequence SEQ ID NO: 22 GPC3-3 BZ CAR nucleic acid sequence SEQ ID NO: 23 GPC3-3 28BZ CAR nucleic acid sequence SEQ ID NO: 24 GPC3-4 CAR nucleic acid sequence SEQ ID NO: 25 GPC3 BZ CAR amino acid sequence (WPRE-deleted) SEQ ID NO: 26 GPC3 BZ CAR nucleic acid sequence (WPRE-deleted) SEQ ID NO: 27 GPC3 VH SEQ ID NO: 28 GPC3 VL SEQ ID NO: 29 GPC3-2 VH SEQ ID NO: 30 GPC3-2 VL SEQ ID NO: 31 GPC3-3 scFv amino acid sequence SEQ ID NO: 32 GPC3-4 scFv amino acid sequence SEQ ID NO: 33 GPC3 scFv nucleic acid sequence SEQ ID NO: 34 GPC3-2 scFv nucleic acid sequence SEQ ID NO: 35 GPC3-3 scFv nucleic acid sequence SEQ ID NO: 36 GPC3-4 scFv nucleic acid sequence SEQ ID NO: 37 GPC3 and GPC3-2 VH CDR1 SEQ ID NO: 38 GPC3 and GPC3-2 VH CDR2 SEQ ID NO: 39 GPC3 and GPC3-2 VH CDR3 SEQ ID NO: 40 GPC3 VL CDR1 SEQ ID NO: 41 GPC3 VL CDR2 SEQ ID NO: 42 GPC3 VL CDR3 SEQ ID NO: 43 GPC3-2 VL CDR1 SEQ ID NO: 44 GPC3-2 VL CDR2 SEQ ID NO: 45 GPC3-2 VL CDR3 SEQ ID NO: 46 GPC3 BZ CAR and Dominant-negative HIF-1α nucleic acid sequence SEQ ID NO: 47 GPC3 BZ CAR and Dominant-negative HIF-1α amino acid sequence
TABLE-US-00003 TABLE 6 Sequences SEQ ID NO: 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMSWVRQAPGKGLEWVSAISGSGGSTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAED TAVYYCARGKRYFDYWGQGTMVTVSSGGGG SGGGGSGGGGSSYELTQPPSASGTPGQRVT ISCSGGSSNIGSNTVNWFRQLPGTAPKLLV YFNNQRPSGVPDRFSGSKSGTSASLAIGGL QSDDEADYYCVAWDDSLNAPVFGGGTKVTV L SEQ ID NO: 2 EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMSWVRQAPGKGLEWVSAISGSGGSTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAED TAVYYCAKGKRYFDYWGQGTMVTVSSGGGG SGGGGSGGGGSQSVLTQPPSASGTPGQRVT ISCSGGSSDIGSNTVNWYQQLPGTAPKLLI YYNNQRPSGVPDRFSGSKSGTSASLAISGL QSEDEADYYCATWDDRMYSPVFGGGTKLTV L SEQ ID NO: 3 MLLLVTSLLLCELPHPAFLLIPGVHSEVQL LESGGGLVQPGGSLRLSCAASGFTFSSYAM SWVRQAPGKGLEWVSAISGSGGSTYYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARGKRYFDYWGQGTMVTVSSGGGGSGGG GSGGGGSSYELTQPPSASGTPGQRVTISCS GGSSNIGSNTVNWFRQLPGTAPKLLVYFNN QRPSGVPDRFSGSKSGTSASLAIGGLQSDD EADYYCVAWDDSLNAPVFGGGTKVTVLESK YGPPCPPCPFWVLVVVGGVLACYSLLVTVA FIIFWVKRGRKKLLYIFKQPFMRPVQTTQE EDGCSCRFPEEEEGGCELRVKFSRSADAPA YQQGQNQLYNELNLGRREEYDVLDKRRGRD PEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYD ALHMQALPPR* SEQ ID NO: 4 MLLLVTSLLLCELPHPAFLLIPGVHSEVQL LESGGGLVQPGGSLRLSCAASGFTFSSYAM SWVRQAPGKGLEWVSAISGSGGSTYYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARGKRYFDYWGQGTMVTVSSGGGGSGGG GSGGGGSSYELTQPPSASGTPGQRVTISCS GGSSNIGSNTVNWFRQLPGTAPKLLVYFNN QRPSGVPDRFSGSKSGTSASLAIGGLQSDD EADYYCVAWDDSLNAPVFGGGTKVTVLESK YGPPCPPCPFWVLVVVGGVLACYSLLVTVA FIIFWVRVKFSRSADAPA* SEQ ID NO: 5 MLLLVTSLLLCELPHPAFLLIPGVHSEVQL LESGGGLVQPGGSLRLSCAASGFTFSSYAM SWVRQAPGKGLEWVSAISGSGGSTYYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARGKRYFDYWGQGTMVTVSSGGGGSGGG GSGGGGSSYELTQPPSASGTPGQRVTISCS GGSSNIGSNTVNWFRQLPGTAPKLLVYFNN QRPSGVPDRFSGSKSGTSASLAIGGLQSDD EADYYCVAWDDSLNAPVFGGGTKVTVLESK YGPPCPPCPFWVLVVVGGVLACYSLLVTVA FIIFWVRSKRSRLLHSDYMNMTPRRPGPTR KHYQPYAPPRDFAAYRSRVKFSRSADAPAY QQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKPRRKNPQEGLYNELQKDKMAEAYSE IGMKGERRRGKGHDGLYQGLSTATKDTYDA LHMQALPPR* SEQ ID NO: 6 MLLLVTSLLLCELPHPAFLLIPGVHSEVQL LESGGGLVQPGGSLRLSCAASGFTFSSYAM SWVRQAPGKGLEWVSAISGSGGSTYYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARGKRYFDYWGQGTMVTVSSGGGGSGGG GSGGGGSSYELTQPPSASGTPGQRVTISCS GGSSNIGSNTVNWFRQLPGTAPKLLVYFNN QRPSGVPDRFSGSKSGTSASLAIGGLQSDD EADYYCVAWDDSLNAPVFGGGTKVTVLESK YGPPCPPCPFWVLVVVGGVLACYSLLVTVA FIIFWVRSKRSRLLHSDYMNMTPRRPGPTR KHYQPYAPPRDFAAYRSKRGRKKLLYIFKQ PFMRPVQTTQEEDGCSCRFPEEEEGGCELR VKFSRSADAPAYQQGQNQLYNELNLGRREE YDVLDKRRGRDPEMGGKPRRKNPQEGLYNE LQKDKMAEAYSEIGMKGERRRGKGHDGLYQ GLSTATKDTYDALHMQALPPR* SEQ ID NO: 7 MLLLVTSLLLCELPHPAFLLIPEVQLLESG GGLVQPGGSLRLSCAASGFTFSSYAMSWVR QAPGKGLEWVSAISGSGGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAK GKRYFDYWGQGTMVTVSSGGGGSGGGGSGG GGSQSVLTQPPSASGTPGQRVTISCSGGSS DIGSNTVNWYQQLPGTAPKLLIYYNNQRPS GVPDRFSGSKSGTSASLAISGLQSEDEADY YCATWDDRMYSPVFGGGTKLTVLESKYGPP CPPCPFWVLVVVGGVLACYSLLVTVAFIIF WVKRGRKKLLYIFKQPFMRPVQTTQEEDGC SCRFPEEEEGGCELRVKFSRSADAPAYQQG QNQLYNELNLGRREEYDVLDKRRGRDPEMG GKPRRKNPQEGLYNELQKDKMAEAYSEIGM KGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR* SEQ ID NO: 8 MLLLVTSLLLCELPHPAFLLIPEVQLLESG GGLVQPGGSLRLSCAASGFTFSSYAMSWVR QAPGKGLEWVSAISGSGGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAK GKRYFDYWGQGTMVTVSSGGGGSGGGGSGG GGSQSVLTQPPSASGTPGQRVTISCSGGSS DIGSNTVNWYQQLPGTAPKLLIYYNNQRPS GVPDRFSGSKSGTSASLAISGLQSEDEADY YCATWDDRMYSPVFGGGTKLTVLESKYGPP CPPCPFWVLVVVGGVLACYSLLVTVAFIIF WVRVKFSRSADAPA* SEQ ID NO: 9 MLLLVTSLLLCELPHPAFLLIPEVQLLESG GGLVQPGGSLRLSCAASGFTFSSYAMSWVR QAPGKGLEWVSAISGSGGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAK GKRYFDYWGQGTMVTVSSGGGGSGGGGSGG GGSQSVLTQPPSASGTPGORVTISCSGGSS DIGSNTVNWYQQLPGTAPKLLIYYNNQRPS GVPDRFSGSKSGTSASLAISGLQSEDEADY YCATWDDRMYSPVFGGGTKLTVLESKYGPP CPPCPFWVLVVVGGVLACYSLLVTVAFIIF WVRSKRSRLLHSDYMNMTPRRPGPTRKHYQ PYAPPRDFAAYRSRVKFSRSADAPAYQQGQ NQLYNELNLGRREEYDVLDKRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMK GERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR* SEQ ID NO: 10 MLLLVTSLLLCELPHPAFLLIPEVQLLESG GGLVQPGGSLRLSCAASGFTFSSYAMSWVR QAPGKGLEWVSAISGSGGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAK GKRYFDYWGQGTMVTVSSGGGGSGGGGSGG GGSQSVLTQPPSASGTPGQRVTISCSGGSS DIGSNTVNWYQQLPGTAPKLLIYYNNQRPS GVPDRFSGSKSGTSASLAISGLQSEDEADY YCATWDDRMYSPVFGGGTKLTVLESKYGPP CPPCPFWVLVVVGGVLACYSLLVTVAFIIF WVRSKRSRLLHSDYMNMTPRRPGPTRKHYQ PYAPPRDFAAYRSKRGRKKLLYIFKQPFMR PVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVL DKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLST ATKDTYDALHMQALPPR* SEQ ID NO: 11 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGGTGTACACTCCGAGGTGCAGCTG TTGGAGTCTGGGGGAGGCTTGGTACAGCCT GGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTAGCAGCTATGCCATG AGCTGGGTCCGCCAGGCTCCAGGGAAGGGG CTGGAGTGGGTCTCAGCTATTAGTGGTAGT GGTGGTAGCACATACTACGCAGACTCCGTG AAGGGCCGGTTCACCATCTCCAGAGACAAT TCCAAGAACACGCTGTATCTGCAAATGAAC AGCCTGAGAGCCGAGGACACGGCCGTGTAT TACTGTGCGAGAGGAAAGCGATACTTTGAC TACTGGGGCCAGGGGACAATGGTCACCGTC TCGAGTGGTGGGGGGGGCAGCGGTGGTGGA GGCTCTGGTGGAGGAGGGAGCTCCTATGAG CTGACTCAGCCACCCTCAGCGTCTGGGACC CCCGGGCAGAGGGTCACCATCTCTTGTTCT GGAGGCAGCTCCAACATCGGAAGTAATACT GTAAACTGGTTCCGGCAGCTCCCAGGAACG GCCCCCAAACTCCTCGTTTATTTTAATAAT CAGCGACCCTCAGGGGTCCCTGACCGATTC TCTGGCTCCAAGTCTGGCACCTCGGCCTCC CTGGCCATCGGTGGGCTCCAGTCTGACGAT GAGGCTGACTATTACTGTGTAGCATGGGAT GACTCTCTGAATGCTCCGGTGTTCGGCGGA GGGACCAAGGTCACCGTCCTAGAGAGCAAA TATGGACCACCATGCCCTCCATGTCCTTTT TGGGTCCTGGTGGTCGTGGGAGGCGTGCTG GCATGTTATTCTCTGCTGGTCACAGTGGCT TTCATCATCTTCTGGGTCAAGCGAGGCCGG AAGAAACTGCTGTACATCTTCAAACAGCCT TTTATGCGCCCAGTGCAGACAACTCAGGAG GAAGACGGCTGCTCTTGTCGGTTCCCCGAG GAAGAGGAAGGGGGATGTGAGCTGCGCGTG AAGTTTTCTCGAAGTGCCGATGCTCCTGCA TATCAGCAGGGACAGAACCAGCTGTACAAC GAGCTGAATCTGGGCCGGAGAGAGGAATAC GACGTGCTGGATAAGAGGCGCGGCAGAGAC CCAGAAATGGGCGGGAAGCCACGACGGAAA AACCCCCAGGAGGGGCTGTATAATGAACTG CAGAAGGACAAAATGGCCGAGGCTTACAGC GAAATCGGGATGAAGGGAGAGAGAAGGCGC GGAAAAGGCCACGATGGACTGTATCAGGGC CTGAGCACTGCCACCAAGGACACCTACGAT GCTCTGCACATGCAGGCACTGCCACCCAGG TGA SEQ ID NO: 12 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGGTGTACACTCCGAGGTGCAGCTG TTGGAGTCTGGGGGAGGCTTGGTACAGCCT GGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTAGCAGCTATGCCATG AGCTGGGTCCGCCAGGCTCCAGGGAAGGGG CTGGAGTGGGTCTCAGCTATTAGTGGTAGT GGTGGTAGCACATACTACGCAGACTCCGTG AAGGGCCGGTTCACCATCTCCAGAGACAAT TCCAAGAACACGCTGTATCTGCAAATGAAC AGCCTGAGAGCCGAGGACACGGCCGTGTAT TACTGTGCGAGAGGAAAGCGATACTTTGAC TACTGGGGCCAGGGGACAATGGTCACCGTC TCGAGTGGTGGGGGGGGCAGCGGTGGTGGA GGCTCTGGTGGAGGAGGGAGCTCCTATGAG CTGACTCAGCCACCCTCAGCGTCTGGGACC CCCGGGCAGAGGGTCACCATCTCTTGTTCT GGAGGCAGCTCCAACATCGGAAGTAATACT GTAAACTGGTTCCGGCAGCTCCCAGGAACG GCCCCCAAACTCCTCGTTTATTTTAATAAT CAGCGACCCTCAGGGGTCCCTGACCGATTC TCTGGCTCCAAGTCTGGCACCTCGGCCTCC CTGGCCATCGGTGGGCTCCAGTCTGACGAT GAGGCTGACTATTACTGTGTAGCATGGGAT GACTCTCTGAATGCTCCGGTGTTCGGCGGA GGGACCAAGGTCACCGTCCTAGAGAGCAAA TATGGACCACCATGCCCTCCATGTCCTTTT TGGGTCCTGGTGGTCGTGGGAGGCGTGCTG GCATGTTATTCTCTGCTGGTCACAGTGGCT TTCATCATCTTCTGGGTCCGCGTGAAGTTT TCTCGAAGTGCCGATGCTCCTGCATGA SEQ ID NO: 13 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGGTGTACACTCCGAGGTGCAGCTG TTGGAGTCTGGGGGAGGCTTGGTACAGCCT GGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTAGCAGCTATGCCATG AGCTGGGTCCGCCAGGCTCCAGGGAAGGGG CTGGAGTGGGTCTCAGCTATTAGTGGTAGT GGTGGTAGCACATACTACGCAGACTCCGTG AAGGGCCGGTTCACCATCTCCAGAGACAAT TCCAAGAACACGCTGTATCTGCAAATGAAC AGCCTGAGAGCCGAGGACACGGCCGTGTAT TACTGTGCGAGAGGAAAGCGATACTTTGAC TACTGGGGCCAGGGGACAATGGTCACCGTC TCGAGTGGTGGGGGGGGCAGCGGTGGTGGA GGCTCTGGTGGAGGAGGGAGCTCCTATGAG CTGACTCAGCCACCCTCAGCGTCTGGGACC CCCGGGCAGAGGGTCACCATCTCTTGTTCT GGAGGCAGCTCCAACATCGGAAGTAATACT GTAAACTGGTTCCGGCAGCTCCCAGGAACG GCCCCCAAACTCCTCGTTTATTTTAATAAT CAGCGACCCTCAGGGGTCCCTGACCGATTC TCTGGCTCCAAGTCTGGCACCTCGGCCTCC CTGGCCATCGGTGGGCTCCAGTCTGACGAT GAGGCTGACTATTACTGTGTAGCATGGGAT GACTCTCTGAATGCTCCGGTGTTCGGCGGA GGGACCAAGGTCACCGTCCTAGAGAGCAAA TATGGACCACCATGCCCTCCATGTCCTTTT TGGGTCCTGGTGGTCGTGGGAGGCGTGCTG GCATGTTATTCCCTGCTGGTCACTGTGGCC TTCATCATCTTCTGGGTGCGGAGCAAGCGG AGCCGGCTGCTGCACTCTGACTACATGAAC ATGACTCCACGGAGACCCGGCCCTACCCGG AAACATTATCAGCCCTACGCCCCACCCAGA GATTTTGCCGCTTATAGGTCCAGGGTGAAG TTTTCTCGCAGTGCAGATGCCCCTGCTTAT CAGCAGGGACAGAATCAGCTGTACAACGAG CTGAATCTGGGCAGGCGCGAGGAATACGAC GTGCTGGATAAGCGACGGGGCAGAGACCCC GAAATGGGAGGGAAGCCCAGAAGGAAAAAC CCTCAGGAGGGGCTGTATAATGAACTGCAG AAGGACAAAATGGCAGAGGCCTACAGTGAA ATCGGGATGAAGGGAGAGCGCCGACGGGGA AAAGGCCACGATGGACTGTATCAGGGCCTG TCTACTGCCACCAAGGACACCTACGATGCC CTGCACATGCAGGCTCTGCCTCCACGCTGA SEQ ID NO: 14 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGGTGTACACTCCGAGGTGCAGCTG TTGGAGTCTGGGGGAGGCTTGGTACAGCCT GGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTAGCAGCTATGCCATG AGCTGGGTCCGCCAGGCTCCAGGGAAGGGG CTGGAGTGGGTCTCAGCTATTAGTGGTAGT GGTGGTAGCACATACTACGCAGACTCCGTG AAGGGCCGGTTCACCATCTCCAGAGACAAT TCCAAGAACACGCTGTATCTGCAAATGAAC AGCCTGAGAGCCGAGGACACGGCCGTGTAT TACTGTGCGAGAGGAAAGCGATACTTTGAC TACTGGGGCCAGGGGACAATGGTCACCGTC TCGAGTGGTGGGGGGGGCAGCGGTGGTGGA GGCTCTGGTGGAGGAGGGAGCTCCTATGAG CTGACTCAGCCACCCTCAGCGTCTGGGACC CCCGGGCAGAGGGTCACCATCTCTTGTTCT GGAGGCAGCTCCAACATCGGAAGTAATACT GTAAACTGGTTCCGGCAGCTCCCAGGAACG GCCCCCAAACTCCTCGTTTATTTTAATAAT CAGCGACCCTCAGGGGTCCCTGACCGATTC TCTGGCTCCAAGTCTGGCACCTCGGCCTCC CTGGCCATCGGTGGGCTCCAGTCTGACGAT GAGGCTGACTATTACTGTGTAGCATGGGAT GACTCTCTGAATGCTCCGGTGTTCGGCGGA GGGACCAAGGTCACCGTCCTAGAGAGCAAA TATGGACCACCATGCCCTCCATGTCCTTTT TGGGTCCTGGTGGTCGTGGGAGGCGTGCTG GCATGTTATTCCCTGCTGGTCACTGTGGCC TTCATCATCTTCTGGGTGCGGAGCAAGCGG AGCCGGCTGCTGCACTCTGACTACATGAAC ATGACTCCACGGAGACCCGGCCCTACCCGG AAACATTATCAGCCCTACGCCCCACCCAGA GATTTTGCCGCTTATAGGTCCAAGCGCGGC CGAAAGAAACTGCTGTACATCTTCAAACAG CCCTTCATGAGACCCGTCCAGACAACTCAG GAGGAAGACGGCTGCAGCTGTAGGTTCCCC GAGGAAGAGGAAGGGGGATGTGAGCTGAGG GTGAAGTTTTCTCGCAGTGCAGATGCCCCT GCTTATCAGCAGGGACAGAATCAGCTGTAC AACGAGCTGAATCTGGGCAGGCGCGAGGAA TACGACGTGCTGGATAAGCGACGGGGCAGA GACCCCGAAATGGGAGGGAAGCCCAGAAGG AAAAACCCTCAGGAGGGGCTGTATAATGAA CTGCAGAAGGACAAAATGGCAGAGGCCTAC AGTGAAATCGGGATGAAGGGAGAGCGCCGA CGGGGAAAAGGCCACGATGGACTGTATCAG GGCCTGTCTACTGCCACCAAGGACACCTAC GATGCCCTGCACATGCAGGCTCTGCCTCCA CGCTGA SEQ ID NO: 15 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGAGGTCCAGCTGCTGGAGAGCGGA GGAGGACTGGTGCAGCCTGGAGGAAGTCTG CGACTGTCATGCGCCGCTAGCGGCTTCACC TTCAGCTCCTATGCAATGAGCTGGGTGCGA CAGGCACCAGGCAAGGGGCTGGAGTGGGTC TCCGCTATCTCCGGCTCTGGAGGCTCTACT TACTATGCAGACAGTGTGAAGGGGCGGTTC ACAATCTCCAGAGATAACTCTAAGAACACT CTGTACCTGCAGATGAACTCTCTGAGAGCT GAGGACACCGCAGTGTACTATTGCGCCAAG GGCAAAAGGTACTTTGATTATTGGGGACAG GGCACTATGGTGACCGTCTCTAGTGGAGGA GGAGGAAGCGGAGGAGGAGGATCCGGCGGA GGAGGCAGTCAGTCAGTGCTGACACAGCCA CCTAGCGCCTCCGGAACCCCAGGACAGCGG GTCACAATCTCTTGTAGTGGGGGATCAAGC GACATTGGGAGCAACACCGTGAATTGGTAT CAGCAGCTGCCTGGAACAGCTCCAAAGCTG CTGATCTACTATAACAATCAGAGGCCCTCC GGCGTCCCTGATCGCTTCTCAGGCAGCAAA TCCGGGACTTCTGCAAGTCTGGCCATTAGT GGCCTGCAGTCAGAGGACGAAGCCGATTAC TATTGTGCTACCTGGGACGATAGGATGTAC TCTCCCGTGTTCGGCGGGGGAACAAAGCTG ACTGTCCTGGAGAGCAAATATGGACCACCA TGCCCTCCATGTCCTTTTTGGGTCCTGGTG GTCGTGGGAGGCGTGCTGGCATGTTATTCT CTGCTGGTCACAGTGGCTTTCATCATCTTC TGGGTCAAGCGAGGCCGGAAGAAACTGCTG TACATCTTCAAACAGCCTTTTATGCGCCCA GTGCAGACAACTCAGGAGGAAGACGGCTGC TCTTGTCGGTTCCCCGAGGAAGAGGAAGGG GGATGTGAGCTGCGCGTGAAGTTTTCTCGA AGTGCCGATGCTCCTGCATATCAGCAGGGA CAGAACCAGCTGTACAACGAGCTGAATCTG GGCCGGAGAGAGGAATACGACGTGCTGGAT AAGAGGCGCGGCAGAGACCCAGAAATGGGC GGGAAGCCACGACGGAAAAACCCCCAGGAG GGGCTGTATAATGAACTGCAGAAGGACAAA ATGGCCGAGGCTTACAGCGAAATCGGGATG AAGGGAGAGAGAAGGCGCGGAAAAGGCCAC GATGGACTGTATCAGGGCCTGAGCACTGCC ACCAAGGACACCTACGATGCTCTGCACATG CAGGCACTGCCACCCAGGTGA SEQ ID NO: 16 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGAGGTCCAGCTGCTGGAGAGCGGA GGAGGACTGGTGCAGCCTGGAGGAAGTCTG CGACTGTCATGCGCCGCTAGCGGCTTCACC TTCAGCTCCTATGCAATGAGCTGGGTGCGA CAGGCACCAGGCAAGGGGCTGGAGTGGGTC TCCGCTATCTCCGGCTCTGGAGGCTCTACT TACTATGCAGACAGTGTGAAGGGGCGGTTC ACAATCTCCAGAGATAACTCTAAGAACACT CTGTACCTGCAGATGAACTCTCTGAGAGCT GAGGACACCGCAGTGTACTATTGCGCCAAG GGCAAAAGGTACTTTGATTATTGGGGACAG GGCACTATGGTGACCGTCTCTAGTGGAGGA GGAGGAAGCGGAGGAGGAGGATCCGGCGGA GGAGGCAGTCAGTCAGTGCTGACACAGCCA CCTAGCGCCTCCGGAACCCCAGGACAGCGG GTCACAATCTCTTGTAGTGGGGGATCAAGC GACATTGGGAGCAACACCGTGAATTGGTAT CAGCAGCTGCCTGGAACAGCTCCAAAGCTG CTGATCTACTATAACAATCAGAGGCCCTCC GGCGTCCCTGATCGCTTCTCAGGCAGCAAA TCCGGGACTTCTGCAAGTCTGGCCATTAGT GGCCTGCAGTCAGAGGACGAAGCCGATTAC TATTGTGCTACCTGGGACGATAGGATGTAC TCTCCCGTGTTCGGCGGGGGAACAAAGCTG ACTGTCCTGGAGAGCAAATATGGACCACCA TGCCCTCCATGTCCTTTTTGGGTCCTGGTG GTCGTGGGAGGCGTGCTGGCATGTTACTCC CTGCTGGTCACTGTGGCCTTCATCATCTTC TGGGTGCGGGTGAAGTTTTCTCGCAGTGCC GACGCTCCCGCATGA SEQ ID NO: 17 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGAGGTCCAGCTGCTGGAGAGCGGA GGAGGACTGGTGCAGCCTGGAGGAAGTCTG CGACTGTCATGCGCCGCTAGCGGCTTCACC TTCAGCTCCTATGCAATGAGCTGGGTGCGA CAGGCACCAGGCAAGGGGCTGGAGTGGGTC TCCGCTATCTCCGGCTCTGGAGGCTCTACT TACTATGCAGACAGTGTGAAGGGGCGGTTC ACAATCTCCAGAGATAACTCTAAGAACACT CTGTACCTGCAGATGAACTCTCTGAGAGCT GAGGACACCGCAGTGTACTATTGCGCCAAG GGCAAAAGGTACTTTGATTATTGGGGACAG GGCACTATGGTGACCGTCTCTAGTGGAGGA GGAGGAAGCGGAGGAGGAGGATCCGGCGGA GGAGGCAGTCAGTCAGTGCTGACACAGCCA CCTAGCGCCTCCGGAACCCCAGGACAGCGG GTCACAATCTCTTGTAGTGGGGGATCAAGC GACATTGGGAGCAACACCGTGAATTGGTAT CAGCAGCTGCCTGGAACAGCTCCAAAGCTG CTGATCTACTATAACAATCAGAGGCCCTCC GGCGTCCCTGATCGCTTCTCAGGCAGCAAA TCCGGGACTTCTGCAAGTCTGGCCATTAGT GGCCTGCAGTCAGAGGACGAAGCCGATTAC TATTGTGCTACCTGGGACGATAGGATGTAC TCTCCCGTGTTCGGCGGGGGAACAAAGCTG ACTGTCCTGGAGAGCAAATATGGACCACCA TGCCCTCCATGTCCTTTTTGGGTCCTGGTG GTCGTGGGAGGCGTGCTGGCATGTTATTCC CTGCTGGTCACAGTGGCCTTCATCATCTTC TGGGTGCGGAGCAAGCGGAGCCGGCTGCTG CACTCTGACTACATGAACATGACCCCCCGG AGACCCGGCCCTACAAGAAAGCATTATCAG CCTTACGCCCCACCCAGGGACTTCGCAGCT TATCGCTCCCGAGTGAAATTTTCTCGCAGT GCAGATGCCCCCGCTTATCAGCAGGGCCAG AATCAGCTGTACAACGAGCTGAATCTGGGG AGGCGCGAGGAATACGACGTGCTGGATAAG CGACGGGGCCGGGACCCCGAAATGGGAGGA AAGCCTAGAAGGAAAAACCCACAGGAGGGC CTGTATAATGAACTGCAGAAGGACAAAATG GCAGAGGCCTACAGCGAAATCGGAATGAAG GGAGAGCGCCGACGGGGCAAAGGACACGAT GGCCTGTATCAGGGGCTGAGCACCGCCACA AAGGACACCTACGATGCCCTGCACATGCAG GCTCTGCCTCCACGCTGA SEQ ID NO: 18 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGAGGTCCAGCTGCTGGAGAGCGGA GGAGGACTGGTGCAGCCTGGAGGAAGTCTG CGACTGTCATGCGCCGCTAGCGGCTTCACC TTCAGCTCCTATGCAATGAGCTGGGTGCGA CAGGCACCAGGCAAGGGGCTGGAGTGGGTC TCCGCTATCTCCGGCTCTGGAGGCTCTACT TACTATGCAGACAGTGTGAAGGGGCGGTTC ACAATCTCCAGAGATAACTCTAAGAACACT CTGTACCTGCAGATGAACTCTCTGAGAGCT GAGGACACCGCAGTGTACTATTGCGCCAAG GGCAAAAGGTACTTTGATTATTGGGGACAG GGCACTATGGTGACCGTCTCTAGTGGAGGA GGAGGAAGCGGAGGAGGAGGATCCGGCGGA GGAGGCAGTCAGTCAGTGCTGACACAGCCA CCTAGCGCCTCCGGAACCCCAGGACAGCGG GTCACAATCTCTTGTAGTGGGGGATCAAGC GACATTGGGAGCAACACCGTGAATTGGTAT CAGCAGCTGCCTGGAACAGCTCCAAAGCTG CTGATCTACTATAACAATCAGAGGCCCTCC GGCGTCCCTGATCGCTTCTCAGGCAGCAAA TCCGGGACTTCTGCAAGTCTGGCCATTAGT GGCCTGCAGTCAGAGGACGAAGCCGATTAC TATTGTGCTACCTGGGACGATAGGATGTAC TCTCCCGTGTTCGGCGGGGGAACAAAGCTG ACTGTCCTGGAGAGCAAATATGGACCACCA TGCCCTCCATGTCCTTTTTGGGTCCTGGTG GTCGTGGGAGGCGTGCTGGCATGTTATTCC CTGCTGGTCACTGTGGCCTTCATCATCTTC TGGGTGCGGAGCAAGCGGAGCCGGCTGCTG CACTCTGACTACATGAACATGACTCCACGG AGACCCGGCCCTACCCGGAAACATTATCAG CCCTACGCCCCACCCAGAGATTTTGCCGCT TATAGGTCCAAGCGCGGCCGAAAGAAACTG CTGTACATCTTCAAACAGCCCTTCATGAGA CCCGTCCAGACAACTCAGGAGGAAGACGGC TGCAGCTGTAGGTTCCCCGAGGAAGAGGAA GGGGGATGTGAGCTGAGGGTGAAGTTTTCT CGCAGTGCAGATGCCCCTGCTTATCAGCAG GGACAGAATCAGCTGTACAACGAGCTGAAT CTGGGCAGGCGCGAGGAATACGACGTGCTG GATAAGCGACGGGGCAGAGACCCCGAAATG GGAGGGAAGCCCAGAAGGAAAAACCCTCAG GAGGGGCTGTATAATGAACTGCAGAAGGAC AAAATGGCAGAGGCCTACAGTGAAATCGGG ATGAAGGGAGAGCGCCGACGGGGAAAAGGC CACGATGGACTGTATCAGGGCCTGTCTACT GCCACCAAGGACACCTACGATGCCCTGCAC ATGCAGGCTCTGCCTCCACGCTGA SEQ ID NO: 19 MLLLVTSLLLCELPHPAFLLIPDVVMTQSP LSLPVTPGEPASISCRSSQSLVHSNRNTYL HWYLQKPGQSPQLLIYKVSNRFSGVPDRFS GSGSGTDFTLKISRVEAEDVGVYYCSQNTH VPPTFGQGTKLEIKGGGGSGGGGSGGGGSQ VQLVQSGAEVKKPGASVKVSCKASGYTFTD YEMHWVRQAPGQGLEWMGALDPKTGDTAYS QKFKGRVTLTADKSTSTAYMELSSLTSEDT AVYYCTRFYSYTYWGQGTLVTVSSDKTHTC PPCPFWVLVVVGGVLACYSLLVTVAFIIFW VKRGRKKLLYIFKQPFMRPVQTTQEEDGCS CRFPEEEEGGCELRVKFSRSADAPAYQQGQ NQLYNELNLGRREEYDVLDKRRGRDPEMGG KPQRRKNPQEGLYNELQKDKMAEAYSEIGM KGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR* SEQ ID NO: 20 MLLLVTSLLLCELPHPAFLLIPDVVMTQSP LSLPVTPGEPASISCRSSQSLVHSNRNTYL HWYLQKPGQSPQLLIYKVSNRFSGVPDRFS GSGSGTDFTLKISRVEAEDVGVYYCSQNTH VPPTFGQGTKLEIKGGGGSGGGGSGGGGSQ VQLVQSGAEVKKPGASVKVSCKASGYTFTD YEMHWVRQAPGQGLEWMGALDPKTGDTAYS QKFKGRVTLTADKSTSTAYMELSSLTSEDT AVYYCTRFYSYTYWGQGTLVTVSSDKTHTC PPCPFWVLVVVGGVLACYSLLVTVAFIIFW VRSKRSRLLHSDYMNMTPRRPGPTRKHYQP YAPPRDFAAYRSKRGRKKLLYIFKQPFMRP VQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLD KRRGRDPEMGGKPQRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLST ATKDTYDALHMQALPPR* SEQ ID NO: 21 MLLLVTSLLLCELPHPAFLLIPQVQLVQSG GGVVQPGRSLRLSCAASGFTFSSYGLHWVR QAPGKGLEWVAAISYDGSKKYYADSVKGRL TISRDNSKNTLYLQMNSLRPDDTALYFCAR GWFVEPLSWGQGTLVTVSSGGGGSGGGGSG GGGSQSVLTQPPSASGTPGORVTISCSGSS SNIGSNTVNWYQQLPGTAPKLLIYSNNQRP SGVPDRFSGSKSGTSASLAISGLQSEDEAD YYCAAWDDSLNGYVFGTGTKLTVLESKYGP PCPPCPFWVLVVVGGVLACYSLLVTVAFII FWVKRGRKKLLYIFKQPFMRPVQTTQEEDG CSCRFPEEEEGGCELRVKFSRSADAPAYQQ GQNQLYNELNLGRREEYDVLDKRRGRDPEM GGKPRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGHDGLYQGLSTATKDTYDALH MQALPPR* SEQ ID NO: 22 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGATGTCGTGATGACGCAGAGCCCT CTCTCTCTTCCCGTTACCCCTGGTGAACCC GCATCAATAAGTTGCCGCTCCAGTCAATCA CTTGTACATTCAAATCGCAATACCTACCTG CACTGGTATTTGCAGAAGCCGGGACAATCC CCTCAATTGTTGATATATAAGGTATCCAAT CGCTTTTCTGGAGTTCCTGATAGATTCAGC GGATCCGGGTCTGGTACTGATTTCACTCTG AAAATATCCAGGGTCGAAGCTGAGGACGTA GGCGTATATTATTGCTCTCAGAACACGCAT GTCCCGCCGACTTTCGGCCAGGGCACTAAA CTTGAGATCAAGGGTGGGGGGGGCAGCGGT GGTGGAGGCTCTGGTGGAGGAGGGAGCCAG GTCCAACTCGTTCAAAGTGGCGCAGAGGTC AAAAAGCCAGGCGCGAGCGTTAAAGTATCA TGTAAGGCCAGCGGTTATACTTTCACTGAT TATGAAATGCACTGGGTGCGACAAGCCCCC GGGCAAGGTCTTGAGTGGATGGGTGCACTT GATCCAAAAACTGGGGATACTGCCTATAGC CAGAAATTCAAAGGGCGCGTCACACTCACT GCCGACAAAAGTACGAGCACAGCTTATATG GAATTGAGTTCACTGACGAGCGAGGATACG GCAGTTTATTACTGTACGCGCTTCTACTCT TACACTTATTGGGGGCAAGGCACTTTGGTT ACTGTGTCCTCTGACAAGACCCATACGTGT CCACCGTGTCCCTTCTGGGTATTGGTTGTG GTCGGCGGTGTCCTTGCTTGTTACAGCCTT CTCGTGACAGTCGCATTCATAATTTTTTGG GTGAAAAGAGGTCGGAAAAAGTTGCTGTAT ATTTTCAAACAACCCTTTATGAGACCTGTA CAAACGACTCAGGAAGAGGATGGTTGTAGT TGCAGGTTTCCGGAGGAGGAGGAAGGTGGG TGCGAACTGCGGGTGAAATTTAGTAGAAGC GCTGACGCACCAGCTTACCAACAAGGACAG AACCAATTGTACAACGAGCTTAACTTGGGT AGGAGGGAGGAATATGATGTACTGGACAAA AGGCGAGGTCGCGATCCGGAAATGGGAGGC AAGCCACAGCGCCGGAAAAACCCGCAGGAA GGCTTGTACAACGAACTTCAGAAAGATAAA ATGGCAGAAGCATACTCCGAAATAGGGATG AAAGGTGAACGGCGGCGAGGCAAGGGCCAC GACGGTCTGTACCAAGGGTTGTCAACGGCA ACTAAAGACACGTATGATGCACTTCATATG CAAGCTCTGCCACCCAGGTGA SEQ ID NO: 23 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGATGTCGTGATGACGCAGAGCCCT CTCTCTCTTCCCGTTACCCCTGGTGAACCC GCATCAATAAGTTGCCGCTCCAGTCAATCA CTTGTACATTCAAATCGCAATACCTACCTG CACTGGTATTTGCAGAAGCCGGGACAATCC CCTCAATTGTTGATATATAAGGTATCCAAT CGCTTTTCTGGAGTTCCTGATAGATTCAGC GGATCCGGGTCTGGTACTGATTTCACTCTG AAAATATCCAGGGTCGAAGCTGAGGACGTA GGCGTATATTATTGCTCTCAGAACACGCAT GTCCCGCCGACTTTCGGCCAGGGCACTAAA CTTGAGATCAAGGGTGGGGGGGGCAGCGGT GGTGGAGGCTCTGGTGGAGGAGGGAGCCAG GTCCAACTCGTTCAAAGTGGCGCAGAGGTC AAAAAGCCAGGCGCGAGCGTTAAAGTATCA TGTAAGGCCAGCGGTTATACTTTCACTGAT TATGAAATGCACTGGGTGCGACAAGCCCCC GGGCAAGGTCTTGAGTGGATGGGTGCACTT GATCCAAAAACTGGGGATACTGCCTATAGC CAGAAATTCAAAGGGCGCGTCACACTCACT GCCGACAAAAGTACGAGCACAGCTTATATG GAATTGAGTTCACTGACGAGCGAGGATACG GCAGTTTATTACTGTACGCGCTTCTACTCT TACACTTATTGGGGGCAAGGCACTTTGGTT ACTGTGTCCTCTGACAAGACCCATACGTGT CCACCGTGTCCCTTCTGGGTATTGGTTGTG GTCGGCGGTGTCCTTGCTTGTTACAGCCTT CTCGTGACAGTCGCATTCATAATTTTTTGG GTGCGGAGCAAGCGGAGCCGGCTGCTGCAC TCTGACTACATGAACATGACTCCACGGAGA CCCGGCCCTACCCGGAAACATTATCAGCCC TACGCCCCACCCAGAGATTTTGCCGCTTAT AGGTCCAAAAGAGGTCGGAAAAAGTTGCTG TATATTTTCAAACAACCCTTTATGAGACCT GTACAAACGACTCAGGAAGAGGATGGTTGT AGTTGCAGGTTTCCGGAGGAGGAGGAAGGT GGGTGCGAACTGCGGGTGAAATTTAGTAGA AGCGCTGACGCACCAGCTTACCAACAAGGA CAGAACCAATTGTACAACGAGCTTAACTTG GGTAGGAGGGAGGAATATGATGTACTGGAC AAAAGGCGAGGTCGCGATCCGGAAATGGGA GGCAAGCCACAGCGCCGGAAAAACCCGCAG GAAGGCTTGTACAACGAACTTCAGAAAGAT AAAATGGCAGAAGCATACTCCGAAATAGGG ATGAAAGGTGAACGGCGGCGAGGCAAGGGC CACGACGGTCTGTACCAAGGGTTGTCAACG GCAACTAAAGACACGTATGATGCACTTCAT ATGCAAGCTCTGCCACCCAGGTGA SEQ ID NO: 24 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTCAGGTCCAGCTTGTGCAAAGCGGA GGAGGAGTGGTACAGCCTGGCCGCTCTTTG AGACTGTCTTGTGCGGCCAGTGGATTTACA TTCTCTTCTTATGGGTTGCATTGGGTCAGA CAAGCACCGGGCAAAGGATTGGAATGGGTC GCGGCCATTAGCTATGATGGCTCAAAGAAA TATTATGCCGATTCCGTAAAAGGGAGGTTG ACAATAAGCCGGGATAACAGCAAGAACACT TTGTATCTTCAGATGAATAGCCTCCGACCG GACGACACGGCACTGTATTTTTGCGCACGC GGGTGGTTTGTAGAACCCCTGAGTTGGGGA CAAGGTACTCTTGTCACGGTATCTTCTGGC GGAGGTGGGAGTGGTGGGGGTGGCAGTGGC GGGGGTGGGTCACAAAGCGTGCTTACACAA CCTCCTTCTGCGAGCGGAACTCCGGGACAA CGGGTTACGATTTCATGCTCCGGCTCAAGT AGCAATATAGGATCAAATACAGTGAATTGG TATCAACAACTCCCTGGCACAGCGCCCAAG CTGCTGATCTACTCTAATAACCAGAGGCCG AGTGGTGTGCCAGATAGGTTCAGTGGCTCT AAATCAGGTACTAGCGCGAGCCTCGCCATT TCAGGACTTCAATCAGAGGATGAAGCGGAC TACTACTGTGCCGCGTGGGATGATTCACTT AATGGATATGTTTTCGGGACCGGAACAAAA TTGACGGTATTGGAGAGCAAATATGGACCA CCATGCCCTCCATGTCCTTTTTGGGTCCTG GTGGTCGTGGGAGGCGTGCTGGCATGTTAT TCTCTGCTGGTCACAGTGGCTTTCATCATC TTCTGGGTCAAGCGAGGCCGGAAGAAACTG CTGTACATCTTCAAACAGCCTTTTATGCGC CCAGTGCAGACAACTCAGGAGGAAGACGGC TGCTCTTGTCGGTTCCCCGAGGAAGAGGAA GGGGGATGTGAGCTGCGCGTGAAGTTTTCT CGAAGTGCCGATGCTCCTGCATATCAGCAG GGACAGAACCAGCTGTACAACGAGCTGAAT CTGGGCCGGAGAGAGGAATACGACGTGCTG GATAAGAGGCGCGGCAGAGACCCAGAAATG GGCGGGAAGCCACGACGGAAAAACCCCCAG GAGGGGCTGTATAATGAACTGCAGAAGGAC AAAATGGCCGAGGCTTACAGCGAAATCGGG ATGAAGGGAGAGAGAAGGCGCGGAAAAGGC CACGATGGACTGTATCAGGGCCTGAGCACT GCCACCAAGGACACCTACGATGCTCTGCAC ATGCAGGCACTGCCACCCAGGTGA SEQ ID NO: 25 MLLLVTSLLLCELPHPAFLLIPEVQLLESG GGLVQPGGSLRLSCAASGFTFSSYAMSWVR QAPGKGLEWVSAISGSGGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAR GKRYFDYWGQGTMVTVSSGGGGSGGGGSGG GGSSYELTQPPSASGTPGQRVTISCSGGSS NIGSNTVNWFRQLPGTAPKLLVYFNNQRPS GVPDRFSGSKSGTSASLAIGGLQSDDEADY YCVAWDDSLNAPVFGGGTKVTVLESKYGPP CPPCPFWVLVVVGGVLACYSLLVTVAFIIF WVKRGRKKLLYIFKQPFMRPVQTTQEEDGC SCRFPEEEEGGCELRVKFSRSADAPAYQQG QNQLYNELNLGRREEYDVLDKRRGRDPEMG GKPRRKNPQEGLYNELQKDKMAEAYSEIGM KGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR SEQ ID NO: 26 ATGCTGCTGCTGGTGACAAGCCTGCTGCTG TGCGAACTGCCCCATCCCGCCTTCCTGCTG ATTCCTGAGGTGCAGCTGTTGGAGTCTGGG GGAGGCTTGGTACAGCCTGGGGGGTCCCTG AGACTCTCCTGTGCAGCCTCTGGATTCACC TTTAGCAGCTATGCCATGAGCTGGGTCCGC CAGGCTCCAGGGAAGGGGCTGGAGTGGGTC TCAGCTATTAGTGGTAGTGGTGGTAGCACA TACTACGCAGACTCCGTGAAGGGCCGGTTC ACCATCTCCAGAGACAATTCCAAGAACACG CTGTATCTGCAAATGAACAGCCTGAGAGCC GAGGACACGGCCGTGTATTACTGTGCGAGA GGAAAGCGATACTTTGACTACTGGGGCCAG GGGACAATGGTCACCGTCTCGAGTGGTGGG GGGGGCAGCGGTGGTGGAGGCTCTGGTGGA GGAGGGAGCTCCTATGAGCTGACTCAGCCA CCCTCAGCGTCTGGGACCCCCGGGCAGAGG GTCACCATCTCTTGTTCTGGAGGCAGCTCC AACATCGGAAGTAATACTGTAAACTGGTTC CGGCAGCTCCCAGGAACGGCCCCCAAACTC CTCGTTTATTTTAATAATCAGCGACCCTCA GGGGTCCCTGACCGATTCTCTGGCTCCAAG TCTGGCACCTCGGCCTCCCTGGCCATCGGT GGGCTCCAGTCTGACGATGAGGCTGACTAT TACTGTGTAGCATGGGATGACTCTCTGAAT GCTCCGGTGTTCGGCGGAGGGACCAAGGTC ACCGTCCTAGAGAGCAAATATGGACCACCA TGCCCTCCATGTCCTTTTTGGGTCCTGGTG GTCGTGGGAGGCGTGCTGGCATGTTATTCT CTGCTGGTCACAGTGGCTTTCATCATCTTC TGGGTCAAGCGAGGCCGGAAGAAACTGCTG TACATCTTCAAACAGCCTTTTATGCGCCCA GTGCAGACAACTCAGGAGGAAGACGGCTGC TCTTGTCGGTTCCCCGAGGAAGAGGAAGGG GGATGTGAGCTGCGCGTGAAGTTTTCTCGA AGTGCCGATGCTCCTGCATATCAGCAGGGA CAGAACCAGCTGTACAACGAGCTGAATCTG GGCCGGAGAGAGGAATACGACGTGCTGGAT AAGAGGCGCGGCAGAGACCCAGAAATGGGC GGGAAGCCACGACGGAAAAACCCCCAGGAG GGGCTGTATAATGAACTGCAGAAGGACAAA ATGGCCGAGGCTTACAGCGAAATCGGGATG AAGGGAGAGAGAAGGCGCGGAAAAGGCCAC GATGGACTGTATCAGGGCCTGAGCACTGCC ACCAAGGACACCTACGATGCTCTGCACATG CAGGCACTGCCACCCAGG SEQ ID NO: 27 EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMSWVRQAPGKGLEWVSAISGSGGSTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAED TAVYYCARGKRYFDYWGQGTMVTVSS SEQ ID NO: 28 SYELTQPPSASGTPGQRVTISCSGGSSNIG SNTVNWFRQLPGTAPKLLVYFNNQRPSGVP DRFSGSKSGTSASLAIGGLQSDDEADYYCV AWDDSLNAPVFGGGTKVTVL SEQ ID NO: 29 EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMSWVRQAPGKGLEWVSAISGSGGSTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAED TAVYYCAKGKRYFDYWGQGTMVTVSS SEQ ID NO: 30 QSVLTQPPSASGTPGQRVTISCSGGSSDIG SNTVNWYQQLPGTAPKLLIYYNNQRPSGVP DRFSGSKSGTSASLAISGLQSEDEADYYCA TWDDRMYSPVFGGGTKLTVL SEQ ID NO: 31 DVVMTQSPLSLPVTPGEPASISCRSSQSLV HSNRNTYLHWYLQKPGQSPQLLIYKVSNRF SGVPDRFSGSGSGTDFTLKISRVEAEDVGV YYCSQNTHVPPTFGQGTKLEIKGGGGSGGG GSGGGGSQVQLVQSGAEVKKPGASVKVSCK ASGYTFTDYEMHWVRQAPGQGLEWMGALDP KTGDTAYSQKFKGRVTLTADKSTSTAYMEL SSLTSEDTAVYYCTRFYSYTYWGQGTLVTV SS SEQ ID NO: 32 QVQLVQSGGGVVQPGRSLRLSCAASGFTFS SYGLHWVRQAPGKGLEWVAAISYDGSKKYY ADSVKGRLTISRDNSKNTLYLQMNSLRPDD TALYFCARGWFVEPLSWGQGTLVTVSSGGG GSGGGGSGGGGSQSVLTQPPSASGTPGQRV TISCSGSSSNIGSNTVNWYQQLPGTAPKLL IYSNNQRPSGVPDRFSGSKSGTSASLAISG LQSEDEADYYCAAWDDSLNGYVFGTGTKLT VL SEQ ID NO: 33 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGC TTGGTACAGCCTGGGGGGTCCCTGAGACTC TCCTGTGCAGCCTCTGGATTCACCTTTAGC AGCTATGCCATGAGCTGGGTCCGCCAGGCT CCAGGGAAGGGGCTGGAGTGGGTCTCAGCT ATTAGTGGTAGTGGTGGTAGCACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATC TCCAGAGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGAGAGCCGAGGAC ACGGCCGTGTATTACTGTGCGAGAGGAAAG CGATACTTTGACTACTGGGGCCAGGGGACA ATGGTCACCGTCTCGAGTGGTGGGGGGGGC AGCGGTGGTGGAGGCTCTGGTGGAGGAGGG AGCTCCTATGAGCTGACTCAGCCACCCTCA GCGTCTGGGACCCCCGGGCAGAGGGTCACC ATCTCTTGTTCTGGAGGCAGCTCCAACATC GGAAGTAATACTGTAAACTGGTTCCGGCAG CTCCCAGGAACGGCCCCCAAACTCCTCGTT TATTTTAATAATCAGCGACCCTCAGGGGTC CCTGACCGATTCTCTGGCTCCAAGTCTGGC ACCTCGGCCTCCCTGGCCATCGGTGGGCTC CAGTCTGACGATGAGGCTGACTATTACTGT GTAGCATGGGATGACTCTCTGAATGCTCCG GTGTTCGGCGGAGGGACCAAGGTCACCGTC CTA SEQ ID NO: 34 GAGGTCCAGCTGCTGGAGAGCGGAGGAGGA CTGGTGCAGCCTGGAGGAAGTCTGCGACTG TCATGCGCCGCTAGCGGCTTCACCTTCAGC TCCTATGCAATGAGCTGGGTGCGACAGGCA CCAGGCAAGGGGCTGGAGTGGGTCTCCGCT ATCTCCGGCTCTGGAGGCTCTACTTACTAT GCAGACAGTGTGAAGGGGCGGTTCACAATC TCCAGAGATAACTCTAAGAACACTCTGTAC CTGCAGATGAACTCTCTGAGAGCTGAGGAC ACCGCAGTGTACTATTGCGCCAAGGGCAAA AGGTACTTTGATTATTGGGGACAGGGCACT ATGGTGACCGTCTCTAGTGGAGGAGGAGGA AGCGGAGGAGGAGGATCCGGCGGAGGAGGC AGTCAGTCAGTGCTGACACAGCCACCTAGC GCCTCCGGAACCCCAGGACAGCGGGTCACA ATCTCTTGTAGTGGGGGATCAAGCGACATT GGGAGCAACACCGTGAATTGGTATCAGCAG CTGCCTGGAACAGCTCCAAAGCTGCTGATC TACTATAACAATCAGAGGCCCTCCGGCGTC CCTGATCGCTTCTCAGGCAGCAAATCCGGG ACTTCTGCAAGTCTGGCCATTAGTGGCCTG CAGTCAGAGGACGAAGCCGATTACTATTGT GCTACCTGGGACGATAGGATGTACTCTCCC GTGTTCGGCGGGGGAACAAAGCTGACTGTC CTG SEQ ID NO: 35 GATGTCGTGATGACGCAGAGCCCTCTCTCT CTTCCCGTTACCCCTGGTGAACCCGCATCA ATAAGTTGCCGCTCCAGTCAATCACTTGTA CATTCAAATCGCAATACCTACCTGCACTGG TATTTGCAGAAGCCGGGACAATCCCCTCAA TTGTTGATATATAAGGTATCCAATCGCTTT TCTGGAGTTCCTGATAGATTCAGCGGATCC GGGTCTGGTACTGATTTCACTCTGAAAATA TCCAGGGTCGAAGCTGAGGACGTAGGCGTA TATTATTGCTCTCAGAACACGCATGTCCCG CCGACTTTCGGCCAGGGCACTAAACTTGAG ATCAAGGGTGGGGGGGGCAGCGGTGGTGGA GGCTCTGGTGGAGGAGGGAGCCAGGTCCAA CTCGTTCAAAGTGGCGCAGAGGTCAAAAAG CCAGGCGCGAGCGTTAAAGTATCATGTAAG GCCAGCGGTTATACTTTCACTGATTATGAA ATGCACTGGGTGCGACAAGCCCCCGGGCAA GGTCTTGAGTGGATGGGTGCACTTGATCCA AAAACTGGGGATACTGCCTATAGCCAGAAA TTCAAAGGGCGCGTCACACTCACTGCCGAC AAAAGTACGAGCACAGCTTATATGGAATTG AGTTCACTGACGAGCGAGGATACGGCAGTT TATTACTGTACGCGCTTCTACTCTTACACT TATTGGGGGCAAGGCACTTTGGTTACTGTG TCCTCT SEQ ID NO: 36 CAGGTCCAGCTTGTGCAAAGCGGAGGAGGA GTGGTACAGCCTGGCCGCTCTTTGAGACTG TCTTGTGCGGCCAGTGGATTTACATTCTCT TCTTATGGGTTGCATTGGGTCAGACAAGCA CCGGGCAAAGGATTGGAATGGGTCGCGGCC ATTAGCTATGATGGCTCAAAGAAATATTAT GCCGATTCCGTAAAAGGGAGGTTGACAATA AGCCGGGATAACAGCAAGAACACTTTGTAT CTTCAGATGAATAGCCTCCGACCGGACGAC ACGGCACTGTATTTTTGCGCACGCGGGTGG TTTGTAGAACCCCTGAGTTGGGGACAAGGT ACTCTTGTCACGGTATCTTCTGGCGGAGGT GGGAGTGGTGGGGGTGGCAGTGGCGGGGGT GGGTCACAAAGCGTGCTTACACAACCTCCT TCTGCGAGCGGAACTCCGGGACAACGGGTT ACGATTTCATGCTCCGGCTCAAGTAGCAAT ATAGGATCAAATACAGTGAATTGGTATCAA CAACTCCCTGGCACAGCGCCCAAGCTGCTG ATCTACTCTAATAACCAGAGGCCGAGTGGT GTGCCAGATAGGTTCAGTGGCTCTAAATCA GGTACTAGCGCGAGCCTCGCCATTTCAGGA CTTCAATCAGAGGATGAAGCGGACTACTAC TGTGCCGCGTGGGATGATTCACTTAATGGA TATGTTTTCGGGACCGGAACAAAATTGACG GTATTG SEQ ID NO: 37 GFTFSSYAMS SEQ ID NO: 38 AISGSGGSTYYADSVKG SEQ ID NO: 39 GKRYFDY SEQ ID NO: 40 SGGSSNIGSNTVN SEQ ID NO: 41 FNNQRPS SEQ ID NO: 42 VAWDDSLNAPV SEQ ID NO: 43 SGGSSDIGSNTVN SEQ ID NO: 44 YNNQRPS SEQ ID NO: 45 ATWDDRMYSPV SEQ ID NO: 46 ATGCGGAGCAAAGAAAGCGAGGTGTTCTAC GAGCTGGCCCACCAACTGCCTCTGCCTCAC AATGTGTCCAGCCACCTGGATAAGGCCAGC GTGATGAGACTGACCATCAGCTACCTGAGA GTGCGGAAGCTGCTGGATGCCGGCGATCTG GACATCGAGGACGATATGAAGGCCCAGATG AACTGCTTCTACCTGAAGGCCCTGGACGGC TTCGTGATGGTGCTGACCGATGACGGCGAC ATGATCTACATCAGCGACAACGTGAACAAG TACATGGGGCTGACCCAGTTCGAGCTGACA GGCCACAGCGTGTTCGACTTCACACACCCC TGCGACCACGAAGAGATGAGAGAGATGCTG ACCCACCGGAACGGCCTGGTCAAGAAGGGC AAAGAGCAGAATACCCAGCGGTCATTCTTC CTGCGGATGAAGTGCACCCTGACCAGCAGG GGCAGAACCATGAACATCAAGAGCGCCACA TGGAAGGTGCTGCACTGCACCGGACACATC CACGTGTACGACACCAACAGCAACCAGCCT CAGTGCGGCTACAAGAAACCTCCTATGACC TGCCTGGTGCTGATCTGCGAGCCCATTCCT CATCCTAGCAACATCGAGATCCCTCTGGAC AGCAAGACCTTCCTGAGCAGACACAGCCTG GACATGAAGTTCAGCTACTGCGACGAGCGG ATCACCGAGCTGATGGGCTATGAGCCTGAA GAACTGCTGGGCCGCAGCATCTACGAGTAC TATCACGCCCTGGACAGCGACCACCTGACC AAGACACACCACGACATGTTCACCAAGGGC CAAGTGACCACCGGCCAGTACAGAATGCTG GCCAAGCGCGGAGGCTACGTGTGGGTTGAA ACACAGGCCACCGTGATCTACAACACCAAG AACTCCCAGCCACAGTGCATCGTGTGCGTG AACTACGTGGTGTCCGGCATCATCCAGCAC GACCTGATCTTCAGCCTGCAGCAGACCGAG TGCGTGCTGAAGCCTGTGGAAAGCAGCGAC ATGAAGATGACCCAGCTGTTTACCAAGGTG GAATCCGAGGACACCAGCAGCCTGTTCGAC AAG SEQ ID NO: 47 MRSKESEVFYELAHQLPLPHNVSSHLDKAS VMRLTISYLRVRKLLDAGDLDIEDDMKAQM NCFYLKALDGFVMVLTDDGDMIYISDNVNK YMGLTQFELTGHSVFDFTHPCDHEEMREML THRNGLVKKGKEQNTQRSFFLRMKCTLTSR GRTMNIKSATWKVLHCTGHIHVYDTNSNQP QCGYKKPPMTCLVLICEPIPHPSNIEIPLD SKTFLSRHSLDMKFSYCDERITELMGYEPE ELLGRSIYEYYHALDSDHLTKTHHDMFTKG QVTTGQYRMLAKRGGYVWVETQATVIYNTK NSQPQCIVCVNYVVSGIIQHDLIFSLQQTE CVLKPVESSDMKMTQLFTKVESEDTSSLFD KIYNTKNSQPQCIVCVNYVVSGIIQHDLIF SLQQTECVLKPVESSDMKMTQLFTKVESED TSSLFDK